

Anthony E Lang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7769391/publications.pdf>

Version: 2024-02-01

976
papers

116,309
citations

204

154
h-index

267

306
g-index

1063
all docs

1063
docs citations

1063
times ranked

57165
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort. <i>Alzheimer's and Dementia</i> , 2023, 19, 226-243.	0.4	15
2	A Novel COVID Era-Related Oromandibular Dyskinesia: Surgical Mask-Induced Dyskinesia?. <i>Canadian Journal of Neurological Sciences</i> , 2022, 49, 470-471.	0.3	3
3	Axial Impairment Following Deep Brain Stimulation in Parkinson's Disease: A Surgicogenomic Approach. <i>Journal of Parkinson's Disease</i> , 2022, 12, 117-128.	1.5	5
4	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 267-282.	1.5	21
5	Longitudinal evaluations of somatosensory-motor inhibition in Dopa-responsive dystonia. <i>Parkinsonism and Related Disorders</i> , 2022, 95, 40-46.	1.1	3
6	Neuroimaging Pearls from the <sc>MDS</sc> Congress Video Challenge. Part 1: Genetic Disorders. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 297-310.	0.8	2
7	Combining Skin α -Synuclein <sc>Real-Time Quaking</sc>-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 648-650.	2.2	12
8	Neuroimaging Pearls from the <sc>MDS</sc> Congress Video Challenge. Part 2: Acquired Disorders. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 311-325.	0.8	2
9	The second family affected with a PRDM8-related disease. <i>Neurological Sciences</i> , 2022, 43, 3847-3855.	0.9	4
10	Deep Bayesian networks for uncertainty estimation and adversarial resistance of white matter hyperintensity segmentation. <i>Human Brain Mapping</i> , 2022, 43, 2089-2108.	1.9	17
11	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. <i>Frontiers in Psychiatry</i> , 2022, 13, 816465.	1.3	3
12	Teaching Video NeuroImage: Unilateral Myorhythmia in a Patient With a Midbrain-Diencephalic Junction Cavernous Malformation. <i>Neurology</i> , 2022, 98, .	1.5	0
13	Lateralized Subthalamic Stimulation for Axial Dysfunction in Parkinson's Disease: A Randomized Trial. <i>Movement Disorders</i> , 2022, , .	2.2	5
14	Patterns of Mixed Pathologies in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 595-607.	1.2	8
15	Case of a Man with Hemichorea and Behavioral Changes: "A Red Herring". <i>Movement Disorders Clinical Practice</i> , 2022, 9, 501-507.	0.8	2
16	Investigating the contribution of white matter hyperintensities and cortical thickness to empathy in neurodegenerative and cerebrovascular diseases. <i>GeroScience</i> , 2022, 44, 1575-1598.	2.1	4
17	Teaching Video NeuroImage: Reversible Caudate Changes in a Patient With Post-Pump Chorea. <i>Neurology</i> , 2022, 98, 731-732.	1.5	0
18	The Role of Insular Cortex in Gut Inflammation Memory: What Does It Mean for Parkinson's Disease?. <i>Movement Disorders</i> , 2022, 37, 700-701.	2.2	1

#	ARTICLE	IF	CITATIONS
19	<sc>DYT4</sc> (Dystonia): Clinical Anthology of 11 Cases and Systematized Review. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 659-675.	0.8	5
20	A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. <i>Movement Disorders</i> , 2022, 37, 1265-1271.	2.2	9
21	Spastic Paraplegia Type 7 and Movement Disorders: Beyond the Spastic Paraplegia. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 522-529.	0.8	6
22	Protracted course progressive supranuclear palsy. <i>European Journal of Neurology</i> , 2022, 29, 2220-2231.	1.7	8
23	Genomic study of a large family with complex neurological phenotype including hearing loss, imbalance and action tremor. <i>Neurobiology of Aging</i> , 2022, 113, 137-142.	1.5	1
24	Small and Large Magnetic Resonance Imaging-Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients. <i>Movement Disorders</i> , 2022, 37, 1304-1309.	2.2	11
25	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148.	2.2	222
26	Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update. <i>Movement Disorders</i> , 2022, 37, 905-935.	2.2	49
27	Î±-Synuclein molecular behavior and nigral proteomic profiling distinguish subtypes of Lewy body disorders. <i>Acta Neuropathologica</i> , 2022, 144, 167-185.	3.9	12
28	The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. <i>Nature Reviews Neurology</i> , 2022, 18, 476-495.	4.9	94
29	Pallidal neuronal activity in multiple system atrophy type P and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 101, 15-17.	1.1	1
30	Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease. <i>JAMA Neurology</i> , 2022, 79, 726.	4.5	0
31	Recommendations for Virtual Administration of the <sc>PSP</sc> Rating Scale. <i>Movement Disorders</i> , 2022, 37, 1960-1961.	2.2	1
32	The Interaction between <sc>HLA-DRB1</sc> and Smoking in Parkinson's Disease Revisited. <i>Movement Disorders</i> , 2022, 37, 1929-1937.	2.2	4
33	Probiotics for Constipation in Parkinson Disease. <i>Neurology</i> , 2021, 96, e772-e782.	1.5	100
34	Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase-Associated Neurodegeneration. <i>Movement Disorders</i> , 2021, 36, 1342-1352.	2.2	20
35	Levodopa challenge test: indications, protocol, and guide. <i>Journal of Neurology</i> , 2021, 268, 3135-3143.	1.8	46
36	Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia. <i>Movement Disorders</i> , 2021, 36, 265-266.	2.2	0

#	ARTICLE	IF	CITATIONS
37	Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 171-177.	2.2	3
38	A Distinct EEG Marker of Celiac Disease-Related Cortical Myoclonus. <i>Movement Disorders</i> , 2021, 36, 999-1005.	2.2	5
39	Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi-Omics. <i>Annals of Neurology</i> , 2021, 89, 546-559.	2.8	99
40	DYT-TUBB4A (DYT4 Dystonia). <i>Neurology</i> , 2021, 96, e1887-e1897.	1.5	9
41	Suggestibility as a valuable criterion for laboratory-supported definite functional movement disorders. <i>Clinical Neurophysiology Practice</i> , 2021, 6, 103-108.	0.6	1
42	Botulinum Toxin-Associated Prolonged Remission of Idiopathic Cervical Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 2021, , 1-5.	0.3	1
43	Improved Segmentation of the Intracranial and Ventricular Volumes in Populations with Cerebrovascular Lesions and Atrophy Using 3D CNNs. <i>Neuroinformatics</i> , 2021, 19, 597-618.	1.5	14
44	Parkinson's Disease and COVID-19: Do We Need to Be More Patient?. <i>Movement Disorders</i> , 2021, 36, 277-277.	2.2	11
45	Bilingualism in Parkinson's disease: Relationship to cognition and quality of life. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2021, 43, 199-212.	0.8	3
46	Is clinical assessment enough? Moving towards early differentiation of neurodegenerative parkinsonisms. <i>Brain</i> , 2021, 144, 1040-1042.	3.7	2
47	Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1125-1125.	2.2	1
48	Proprioceptive recalibration following implicit visuomotor adaptation is preserved in Parkinson's disease. <i>Experimental Brain Research</i> , 2021, 239, 1551-1565.	0.7	9
49	Reply to: "The Logic and Pitfalls of Parkinson's as Brain- Versus Body-Subtypes". <i>Movement Disorders</i> , 2021, 36, 786-787.	2.2	2
50	Dream Enactment Behavior Disorder Associated with Pallido-Nigro-Lusian Degeneration and Tau Proteinopathy. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 594-599.	0.8	2
51	The Logic and Pitfalls of Parkinson's Disease as "Brain- Versus "Body-Subtypes". <i>Movement Disorders</i> , 2021, 36, 594-598.	2.2	28
52	Teaching Video NeuroImage: "Weighing-in on an Unusual Tremor. <i>Neurology</i> , 2021, 97, e970-e971.	1.5	1
53	Exacerbation of Stiff Person Syndrome by Selective Serotonin Reuptake Inhibitors. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 772-774.	0.8	1
54	Preferences for Communication About End-of-Life Care in Atypical Parkinsonism. <i>Movement Disorders</i> , 2021, 36, 2116-2125.	2.2	4

#	ARTICLE	IF	CITATIONS
55	Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?. <i>Movement Disorders</i> , 2021, 36, 1483-1484.	2.2	17
56	Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. <i>Movement Disorders</i> , 2021, 36, 1964-1967.	2.2	4
57	Periodic Alternating Gaze Deviation Due to Paraneoplastic Cerebellar Degeneration. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 791-793.	0.8	1
58	Spinocerebellar Ataxia 40: Another Etiology Underlying Essential Tremor Syndrome. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 944-946.	0.8	4
59	Genomewide Association Studies of <i>LRRK2</i> Modifiers of Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 76-88.	2.8	30
60	Multimodal Longitudinal Neurophysiological Investigations in Dopamine-Responsive Dystonia. <i>Movement Disorders</i> , 2021, 36, 1986-1987.	2.2	3
61	Hyperglycemic hemichorea presenting with normal MRI and striatal hyperdensity on CT. <i>Neurological Sciences</i> , 2021, 42, 4341-4343.	0.9	0
62	Movement Disorders Associated with Hypogonadism. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 997-1011.	0.8	7
63	Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2419-2425.	2.2	11
64	Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7292.	1.8	7
65	MRI-visible perivascular space volumes, sleep duration and daytime dysfunction in adults with cerebrovascular disease. <i>Sleep Medicine</i> , 2021, 83, 83-88.	0.8	11
66	Neuropsychiatric disorders and COVID-19. <i>Lancet Psychiatry</i> , 2021, 8, 564-565.	3.7	2
67	Short-term deceleration capacity of heart rate: a sensitive marker of cardiac autonomic dysfunction in idiopathic Parkinson's disease. <i>Clinical Autonomic Research</i> , 2021, 31, 729-736.	1.4	2
68	Irreversible extreme freezing of gait after dopamine agonist withdrawal. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04712.	0.2	1
69	The Discovery of α -Synuclein in Lewy Pathology of Parkinson's Disease: The Inspiration of a Revolution. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1189-1193.	0.8	1
70	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. <i>Nature Medicine</i> , 2021, 27, 1451-1457.	15.2	63
71	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 926.	3.8	80
72	Contribution of rare variant associations to neurodegenerative disease presentation. <i>Npj Genomic Medicine</i> , 2021, 6, 80.	1.7	14

#	ARTICLE	IF	CITATIONS
73	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. <i>Neurobiology of Aging</i> , 2021, 105, 378.e1-378.e9.	1.5	8
74	Diagnosing functional neurological disorder: seeing the whole picture. <i>CNS Spectrums</i> , 2021, 26, 593-600.	0.7	10
75	Differences in Drug Pharmacokinetics and Motor Fluctuation in DYT-1 GCH1. <i>Canadian Journal of Neurological Sciences</i> , 2021, 48, 734-736.	0.3	0
76	Identical twins with progressive kyphoscoliosis and ophthalmoplegia. <i>Parkinsonism and Related Disorders</i> , 2021, 92, 119-122.	1.1	1
77	Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial. <i>BMC Neurology</i> , 2021, 21, 459.	0.8	9
78	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. <i>Neurology</i> , 2021, 97, 942-957.	1.5	58
79	Differential cognitive correlates of tau and neurofilament light chain in cerebrospinal fluid of frontotemporal lobar degeneration patients with and without Alzheimer's markers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
80	Tongue Protrusion Dystonia in Pantothenate Kinase-Associated Neurodegeneration. <i>Pediatric Neurology</i> , 2020, 103, 76-78.	1.0	5
81	Expert comment to: Novel Xp21.1 deletion associated with unusual features in large McLeod syndrome kindred. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 133-134.	1.1	2
82	Validation of the Movement Disorder Society Criteria for the Diagnosis of Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	2.2	37
83	What Is the Role of a Specialist Assessment Clinic for FND? Lessons From Three National Referral Centers. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 79-84.	0.9	44
84	Integrated Therapy for Functional Movement Disorders: Time for a Change. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 169-174.	0.8	27
85	Interhemispheric pathways in agenesis of the corpus callosum and Parkinson's disease. <i>Brain Stimulation</i> , 2020, 13, 360-362.	0.7	3
86	Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 105-118.	1.0	18
87	Late-Onset Mitochondrial Membrane Protein-Associated Neurodegeneration With Extensive Brain Iron Deposition. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 120-121.	0.8	3
88	Recurrent neurologic symptoms complicating venom immunotherapy in a patient with systemic mastocytosis and severe Hymenoptera allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 780-782.	2.0	1
89	Outcome Measures for Functional Neurological Disorder: A Review of the Theoretical Complexities. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 33-42.	0.9	65
90	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 200-203.	1.1	8

#	ARTICLE	IF	CITATIONS
91	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 121-126.	1.1	11
92	Preface to the Video Challenge Supplement for <i>Movement Disorders Clinical Practice</i> . <i>Movement Disorders Clinical Practice</i> , 2020, 7, S53-S54.	0.8	0
93	â€œOpeningâ€•New Insights Into <i>LRRK2</i> Conformation and the Microtubule. <i>Movement Disorders</i> , 2020, 35, 2162-2163.	2.2	0
94	Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD). <i>Journal of Parkinson's Disease</i> , 2020, 10, 1561-1569.	1.5	4
95	Nonsteroidal Anti-inflammatory Use and <i>LRRK2</i> Parkinson's Disease Penetrance. <i>Movement Disorders</i> , 2020, 35, 1755-1764.	2.2	57
96	Initiating pharmacotherapy in early Parkinson's disease. <i>Lancet Neurology</i> , The, 2020, 19, 643-644.	4.9	2
97	The retina as a window to the basal ganglia: Systematic review of the potential link between retinopathy and hyperkinetic disorders in diabetes. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 194-198.	1.1	8
98	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 127-132.	1.1	10
99	Twinkle-associated familial parkinsonism with Lewy pathology. <i>Neurology</i> , 2020, 95, 644-647.	1.5	6
100	Telemedicine in Movement Disorders: Leçons du COVID-19. <i>Movement Disorders</i> , 2020, 35, 1893-1896.	2.2	24
101	<i>Helicobacter pylori</i> Eradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial. <i>Movement Disorders</i> , 2020, 35, 2250-2260.	2.2	45
102	Reply to: â€œA New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disordersâ€•. <i>Movement Disorders</i> , 2020, 35, 1903-1904.	2.2	9
103	Abnormal brain structure mediates the association between ApoE4 and slow gait among patients with pathological cognitive impairment: Results from the Ontario Neurodegenerative Research Initiative. <i>Alzheimer's and Dementia</i> , 2020, 16, e044540.	0.4	0
104	Phenotype differences between corticobasal syndrome and progressive supranuclear palsy with and without Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2020, 16, e046071.	0.4	0
105	Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. <i>Frontiers in Neurology</i> , 2020, 11, 572976.	1.1	65
106	Heart rate variability biomarkers of leucine-rich repeat kinase 2-associated Parkinson's disease. , 2020, , .		0
107	Age-Related Parkinsonian Signs in Microdeletion 22q11.2. <i>Movement Disorders</i> , 2020, 35, 1239-1245.	2.2	4
108	The evidence for multidisciplinary care in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 539-549.	1.4	14

#	ARTICLE	IF	CITATIONS
109	Movement Disorders and Renal Diseases. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 763-779.	0.8	13
110	Parkinson's Disease, <scp><i>NOTCH3</i></scp> Genetic Variants, and White Matter Hyperintensities. <i>Movement Disorders</i> , 2020, 35, 2090-2095.	2.2	18
111	Forecasts for the Attainment of Major Research Milestones in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1047-1055.	1.5	3
112	GDNF and Parkinsonâ€™s Disease: Where Next? A Summary from a Recent Workshop. <i>Journal of Parkinson's Disease</i> , 2020, 10, 875-891.	1.5	63
113	Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: changes in the last decade. <i>European Journal of Neurology</i> , 2020, 27, 975-984.	1.7	41
114	Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. <i>Lancet Neurology</i> , The, 2020, 19, 452-461.	4.9	104
115	Outcome measurement in functional neurological disorder: a systematic review and recommendations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 638-649.	0.9	77
116	PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. <i>Frontiers in Neurology</i> , 2020, 11, 574.	1.1	7
117	Movement Disorders Due to Selective Basal Ganglia Lesions with Uremia. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 350-365.	0.3	13
118	Disease modification and biomarker development in Parkinson disease. <i>Neurology</i> , 2020, 94, 481-494.	1.5	103
119	Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2020, 94, 144-145.	1.5	2
120	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 44-45.	1.1	6
121	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency? Response from the authors. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 80.	1.1	2
122	Adult-onset neuronal intranuclear inclusion disease mimicking Fragile X-associated tremor-ataxia syndrome in ethnic Chinese patients. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 25-27.	1.1	15
123	Primary brain calcification due to a homozygous MYORG mutation causing isolated paroxysmal kinesigenic dyskinesia. <i>Brain</i> , 2020, 143, e36-e36.	3.7	7
124	Isolated Ear Clicks with Partial Voluntary Control. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 10, 55.	1.1	0
125	Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease. <i>Neuropharmacology</i> , 2019, 147, 11-27.	2.0	26
126	TheÂMovement disorder associated with NMDAR antibody-encephalitis is complex and characteristic: an expert video-rating study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 724-726.	0.9	71

#	ARTICLE	IF	CITATIONS
127	Single-pulse subthalamic deep brain stimulation reduces premotor-motor facilitation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 224-227.	1.1	3
128	Amantadine for Gait Dysfunction in Pantothenate Kinase-Associated Neurodegeneration. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 782-784.	0.3	2
129	Dancing Dorsal Quadrilateralsâ€”Organic or Functional?â€”Reply. <i>JAMA Neurology</i> , 2019, 76, 985.	4.5	0
130	Deep brain stimulation in status dystonicus caused by anti-NMDA receptor encephalitis. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 255-257.	1.1	6
131	ADCY5â€”Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 512-520.	0.8	31
132	Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, and Healthy Controls. <i>Frontiers in Neuroscience</i> , 2019, 13, 1259.	1.4	29
133	Clinical and neural responses to cognitive behavioral therapy for functional tremor. <i>Neurology</i> , 2019, 93, e1787-e1798.	1.5	73
134	Reply to â€œStudying reproducibility of data-driven Parkinson's disease subtypesâ€. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 245-246.	1.1	0
135	<p>Orthostatic hypotension and dementia incidence: links and implications</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2181-2194.	1.0	17
136	Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinsonâ€™s disease. <i>Clinical Autonomic Research</i> , 2019, 29, 603-614.	1.4	10
137	Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. <i>Translational Neurodegeneration</i> , 2019, 8, 28.	3.6	70
138	Tics and functional tic-like movements. <i>Neurology</i> , 2019, 93, 750-758.	1.5	89
139	Cortical GABAergic dysfunction underlying abnormal hand movements in ARX mutation. <i>Clinical Neurophysiology</i> , 2019, 130, 1750-1751.	0.7	1
140	Randomized Delayed-Start Trial of Levodopa in Parkinsonâ€™s Disease. <i>New England Journal of Medicine</i> , 2019, 380, 315-324.	13.9	225
141	Diagnostic delay in Parkinson's disease caused by PRKN mutations. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 217-220.	1.1	21
142	Genetic Variation in the Ontario Neurodegenerative Disease Research Initiative. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 491-498.	0.3	7
143	Bioinformatics-Based Identification of Expanded Repeats: A Non-reference Intronic Pentamer Expansion in RFC1 Causes CANVAS. <i>American Journal of Human Genetics</i> , 2019, 105, 151-165.	2.6	170
144	Using global team science to identify genetic parkinson's disease worldwide. <i>Annals of Neurology</i> , 2019, 86, 153-157.	2.8	26

#	ARTICLE	IF	CITATIONS
145	Gelastic Cataplexy in Niemann Pick Type C. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 498-499.	0.8	1
146	Parkinson's disease in the Western Pacific Region. <i>Lancet Neurology</i> , The, 2019, 18, 865-879.	4.9	116
147	The clinical significance of lower limb tremors. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 165-171.	1.1	7
148	Hiding in Plain Sight: Functional Neurological Disorders in the News. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019, 31, 361-367.	0.9	13
149	Dystonia and Parkinson's disease: What is the relationship?. <i>Neurobiology of Disease</i> , 2019, 132, 104462.	2.1	71
150	Paroxysmal Asymmetric Dystonic Arm Posturing—A Less Recognized but Characteristic Manifestation of ATP1A3-related disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 312-315.	0.8	15
151	Isolated Abdominal Motor Seizures of Mesial Parietal Origin: Epileptic Belly Dancing?. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 396-399.	0.8	4
152	Jumping to overcome freezing of gait while turning in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 349-351.	1.1	2
153	Tremor with congenital mirror movements: evidence of involvement of the primary motor cortex in tremor. <i>European Journal of Neurology</i> , 2019, 26, e66-e67.	1.7	0
154	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	2.2	73
155	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019, 34, 676-681.	2.2	43
156	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	2.2	93
157	The Waiting Room: neurological observations made outside the movement disorder specialist's consulting office. <i>Practical Neurology</i> , 2019, 19, 295-301.	0.5	6
158	Diffuse Brain Calcification, a Novel SLC20A2 Variant, Vertical Supranuclear Gaze Palsy, and Systemic Lupus Erythematosus. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 403-405.	0.8	2
159	Successful spinal cord stimulation for severe medication-refractory restless legs syndrome. <i>Movement Disorders</i> , 2019, 34, 585-586.	2.2	8
160	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019, 92, 329-337.	1.5	194
161	Corticobasal degeneration. <i>International Review of Neurobiology</i> , 2019, 149, 87-136.	0.9	24
162	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 138-145.	1.1	7

#	ARTICLE	IF	CITATIONS
163	Dancing Dorsal Quadrilaterals. <i>JAMA Neurology</i> , 2019, 76, 351.	4.5	11
164	Successful pallidotomy for post-hyperglycemic hemichorea-ballism. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 228-230.	1.1	6
165	Soft signs in movement disorders: friends or foes?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 961-962.	0.9	24
166	Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway. <i>Neurobiology of Disease</i> , 2019, 124, 176-182.	2.1	14
167	Beta-propeller protein associated neurodegeneration (BPAN); the first report of three patients from Iran with de novo novel mutations. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 231-233.	1.1	6
168	Gut-brain axis and the spread of α -synuclein pathology: Vagal highway or dead end?. <i>Movement Disorders</i> , 2019, 34, 307-316.	2.2	144
169	Therapeutic trial design for frontotemporal dementia and related disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 412-423.	0.9	21
170	Opsoclonus-myoclonus-encephalopathy induced by cefepime. <i>Journal of the Neurological Sciences</i> , 2019, 396, 33-35.	0.3	10
171	Isolated lingual myoclonus in an HIV patient. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 241-244.	1.1	1
172	Linacotide and Prucalopride for Management of Constipation in Patients with Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 218-220.	0.8	23
173	Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. <i>Movement Disorders</i> , 2018, 33, 960-965.	2.2	12
174	A 21-Year Retrospective Study of the Toronto Western Hospital Deep Brain Stimulation Cohort. <i>Movement Disorders</i> , 2018, 33, 850-852.	2.2	4
175	Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	17
176	Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. <i>Movement Disorders</i> , 2018, 33, 660-677.	2.2	275
177	Pallidal deep brain stimulation modulates cortical excitability and plasticity. <i>Annals of Neurology</i> , 2018, 83, 352-362.	2.8	51
178	Infantile-onset hand dystonia with intellectual disability. <i>Neurology</i> , 2018, 90, 333-335.	1.5	3
179	Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease. <i>Cmaj</i> , 2018, 190, E50-E52.	0.9	6
180	CLIPPERS: A Treatable Cause of Spastic Ataxia. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 212-214.	0.8	1

#	ARTICLE	IF	CITATIONS
181	Ataxiaâ€telangiectasia: A review of movement disorders, clinical features, and genotype correlations. <i>Movement Disorders</i> , 2018, 33, 1238-1247.	2.2	90
182	What is â€œessentialâ€about essential tremor? A diagnostic placeholder. <i>Movement Disorders</i> , 2018, 33, 58-61.	2.2	37
183	Oculogyric crises in PLA2G6 associated neurodegeneration. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 111-112.	1.1	8
184	Functional neurological disorders in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 566-571.	0.9	76
185	Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study. <i>NeuroImage: Clinical</i> , 2018, 17, 179-187.	1.4	67
186	Altered gut microbiome and metabolome in patients with multiple system atrophy. <i>Movement Disorders</i> , 2018, 33, 174-176.	2.2	45
187	[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. <i>Brain Structure and Function</i> , 2018, 223, 589-595.	1.2	36
188	Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathies. <i>Neuroscience Letters</i> , 2018, 665, 18-21.	1.0	33
189	Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence. <i>Journal of Parkinson's Disease</i> , 2018, 8, S59-S64.	1.5	48
190	Neurostimulation for Functional Neurological Disorder: Evaluating Longitudinal Neurophysiology. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 561-563.	0.8	6
191	Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 1123.	1.1	19
192	Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 503-510.	1.5	18
193	Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitiveâ€enhancing medications. <i>Movement Disorders</i> , 2018, 33, 1769-1776.	2.2	36
194	Levodopaâ€induced dyskinesia in Parkinson disease: Current and evolving concepts. <i>Annals of Neurology</i> , 2018, 84, 797-811.	2.8	225
195	Systematic review of movement disorders and oculomotor abnormalities in Whipple's disease. <i>Movement Disorders</i> , 2018, 33, 1700-1711.	2.2	25
196	Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 2146-2159.	0.7	25
197	Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinsonâ€™s disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5164-E5173.	3.3	83
198	Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment. <i>Current Opinion in Neurology</i> , 2018, 31, 484-490.	1.8	69

#	ARTICLE	IF	CITATIONS
199	Pantothenate kinase-associated neurodegeneration mimicking Tourette syndrome: a case report and review of the literature. <i>Neurological Sciences</i> , 2018, 39, 1797-1800.	0.9	7
200	Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 109-110.	1.1	53
201	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 102-106.	1.1	63
202	Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimer's Disease and Parkinson's Disease Affect Caregiver Mood and Burden. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 120.	1.7	64
203	Smoldering Multiple Myeloma Associated Leukoencephalopathy Presenting with Holmes Tremor, Ataxia, and Pyramidal Syndrome. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 433-435.	0.8	3
204	Sleep-related motor and behavioral disorders: Recent advances and new entities. <i>Movement Disorders</i> , 2018, 33, 1042-1055.	2.2	12
205	Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. <i>Neurology</i> , 2018, 90, e2059-e2067.	1.5	35
206	Diagnostic criteria for camptocormia in Parkinson's disease: A consensus-based proposal. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 53-57.	1.1	38
207	Brain tissue pulsatility is related to clinical features of Parkinson's disease. <i>NeuroImage: Clinical</i> , 2018, 20, 222-227.	1.4	5
208	[¹⁸ F]AV-1451 binding and postmortem pathology of CBD. <i>Movement Disorders</i> , 2018, 33, 1360-1361.	2.2	5
209	Comment on "Is it Useful to Classify PSP and CBD as Different Disorders?" <i>Movement Disorders Clinical Practice</i> , 2018, 5, 564-565.	0.8	4
210	ADCK3-related Coenzyme Q10 Deficiency: A Potentially Treatable Genetic Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 635-639.	0.8	25
211	Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice. <i>Movement Disorders</i> , 2018, 33, 1195-1203.	2.2	3
212	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	2.2	114
213	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1601-1608.	2.2	171
214	Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. <i>JAMA Neurology</i> , 2018, 75, 1132.	4.5	455
215	Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. <i>Journal of Parkinson's Disease</i> , 2018, 8, 131-139.	1.5	10
216	Movement disorders in non-encephalopathic Hashimoto's thyroiditis. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 141-142.	1.1	16

#	ARTICLE	IF	CITATIONS
217	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <i>Journal of Neural Transmission</i> , 2018, 125, 1373-1379.	1.4	25
218	Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 58-64.	1.1	71
219	Precision medicine for disease modification in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 119-126.	4.9	141
220	Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 610-614.	2.2	18
221	Essential pitfalls in "essential" tremor. <i>Movement Disorders</i> , 2017, 32, 325-331.	2.2	74
222	Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3150-3160.	2.4	48
223	Pedunculopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 613-616.	0.9	24
224	Oculogyric crises: A review of phenomenology, etiology, pathogenesis, and treatment. <i>Movement Disorders</i> , 2017, 32, 193-202.	2.2	31
225	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , 2017, 32, 319-324.	2.2	145
226	AAV1/2-induced overexpression of A53T- α -synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2017, 5, 11.	2.4	105
227	Adult motor phenotype differentiates Dravet syndrome from Lennox-Gastaut syndrome and links <i>SCN1A</i> to early onset parkinsonian features. <i>Epilepsia</i> , 2017, 58, e44-e48.	2.6	32
228	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	2.2	121
229	Common Myths in the Use of Levodopa in Parkinson Disease. <i>JAMA Neurology</i> , 2017, 74, 633.	4.5	60
230	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	2.2	1,402
231	Prediction of cognition in Parkinson's disease with a clinical "genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology</i> , The, 2017, 16, 620-629.	4.9	131
232	Tremor-Dominant Pantothenate Kinase-associated Neurodegeneration. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 772-774.	0.8	5
233	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. <i>Lancet Neurology</i> , The, 2017, 16, 552-563.	4.9	303
234	Tracking the course of prodromal Parkinson's disease. <i>Brain</i> , 2017, 140, 259-262.	3.7	5

#	ARTICLE	IF	CITATIONS
235	Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. <i>Translational Neurodegeneration</i> , 2017, 6, 8.	3.6	177
236	Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 893-903.	2.2	29
237	Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease. <i>Brain</i> , 2017, 140, 1371-1383.	3.7	41
238	Parkinson disease. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17013.	18.1	3,048
239	Placebos in clinical trials: unravelling a complex phenomenon. <i>Lancet Neurology</i> , The, 2017, 16, 28-29.	4.9	6
240	Alternating Hemiplegia of Childhood as a New Presentation of Adenylate Cyclase 5-Mutation-Associated Disease: A Report of Two Cases. <i>Journal of Pediatrics</i> , 2017, 181, 306-308.e1.	0.9	24
241	The Ontario Neurodegenerative Disease Research Initiative (ONDRI). <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 196-202.	0.3	72
242	Basal ganglia calcification in a case of PKAN. <i>Parkinsonism and Related Disorders</i> , 2017, 36, 98-99.	1.1	9
243	Levodopa and Parkinson Disease's "Myths Revisited" Reply. <i>JAMA Neurology</i> , 2017, 74, 1270.	4.5	2
244	Caffeine as symptomatic treatment for Parkinson disease (Caf@PD). <i>Neurology</i> , 2017, 89, 1795-1803.	1.5	102
245	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	2.2	608
246	Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration. <i>Annals of Neurology</i> , 2017, 82, 503-513.	2.8	133
247	Alcohol improves cerebellar learning deficit in myoclonus-dystonia: A clinical and electrophysiological investigation. <i>Annals of Neurology</i> , 2017, 82, 543-553.	2.8	39
248	Progressive ataxia and palatal tremor: Two autopsy cases of a novel tauopathy. <i>Movement Disorders</i> , 2017, 32, 1465-1473.	2.2	19
249	Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 447-448.	0.3	3
250	Is there even such a thing as "idiopathic normal pressure hydrocephalus"? <i>Annals of Neurology</i> , 2017, 82, 1032-1032.	2.8	2
251	A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY@PD III). <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 360-368.	1.7	59
252	Will New Genetic Techniques Like Exome Sequencing Obviate the Need for Clinical Expertise? No. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 39-41.	0.8	3

#	ARTICLE	IF	CITATIONS
253	Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes. <i>Human Brain Mapping</i> , 2017, 38, 283-292.	1.9	30
254	Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). <i>Journal of Alzheimer's Disease</i> , 2017, 59, 707-721.	1.2	54
255	[18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 440.	1.7	58
256	Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0173944.	1.1	17
257	A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0178982.	1.1	11
258	Asymmetric neuromodulation of motor circuits in Parkinson's disease: The role of subthalamic deep brain stimulation. , 2017, 8, 261.		18
259	The long-term outcome of orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309942.	0.9	100
260	Disrupted Nodal and Hub Organization Account for Brain Network Abnormalities in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 259.	1.7	53
261	Deficits in the Mimicry of Facial Expressions in Parkinson's Disease. <i>Frontiers in Psychology</i> , 2016, 7, 780.	1.1	40
262	Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. <i>Lancet Neurology</i> , The, 2016, 15, 954-966.	4.9	100
263	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , 2016, 31, 1272-1282.	2.2	464
264	A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia. <i>Neurogenetics</i> , 2016, 17, 245-249.	0.7	21
265	Parkinson's disease-related fatigue: A case definition and recommendations for clinical research. <i>Movement Disorders</i> , 2016, 31, 625-631.	2.2	89
266	Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 116-124.	0.8	22
267	Launching the movement disorders society genetic mutation database (MDSGene). <i>Movement Disorders</i> , 2016, 31, 607-609.	2.2	54
268	Focal Predominant Forms of Posthypoxic Action Myoclonus. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 417-420.	0.8	1
269	Paroxysmal Hemiballism/Hemichorea Resulting from Transient Ischemic Attacks. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 303-305.	0.8	8
270	Augmented Restless Legs Syndrome with Marked Hyperkinesias and Impulsive/Compulsive Behaviors. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 412-414.	0.8	1

#	ARTICLE	IF	CITATIONS
271	<scp>N</scp>omenclature of genetic movement disorders: <scp>R</scp>ecommendations of the international <scp>P</scp>arkinson and movement disorder society task force. Movement Disorders, 2016, 31, 436-457.	2.2	228
272	Contribution of insula in Parkinson's disease: A quantitative meta-analysis study. Human Brain Mapping, 2016, 37, 1375-1392.	1.9	36
273	Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects. Movement Disorders, 2016, 31, 290-298.	2.2	68
274	Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study. Movement Disorders, 2016, 31, 1243-1247.	2.2	48
275	â€œUnder pressureâ€™: is there a link between orthostatic hypotension and cognitive impairment in Î±-synucleinopathies?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1311-1321.	0.9	75
276	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinsonâ€™s disease: a pharmacogenetic study. Brain, 2016, 139, 2050-2062.	3.7	53
277	The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurology, The, 2016, 15, 546-548.	4.9	82
278	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism and Related Disorders, 2016, 28, 41-48.	1.1	33
279	Deep Brain Stimulation in Rare Inherited Dystonias. Brain Stimulation, 2016, 9, 905-910.	0.7	39
280	Abolishing the 1â€™year rule: How much evidence will be enough?. Movement Disorders, 2016, 31, 1623-1627.	2.2	43
281	A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia. Brain, 2016, 139, 2609-2616.	3.7	9
282	Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease. Movement Disorders Clinical Practice, 2016, 3, 53-58.	0.8	1
283	Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. Movement Disorders, 2016, 31, 538-546.	2.2	91
284	Long-term double-blinded unilateral pedunculopontine area stimulation in Parkinson's disease. Movement Disorders, 2016, 31, 1570-1574.	2.2	47
285	Reply letter to Jinnah â€™Locus pocusâ€™ and Albanese â€™Complex dystonia is not a category in the new 2013 consensus classificationâ€™: Necessary evolution, no magic!. Movement Disorders, 2016, 31, 1760-1762.	2.2	1
286	Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. Annals of Neurology, 2016, 80, 674-685.	2.8	226
287	Neurologic diagnostic criteria for functional neurologic disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 139, 193-212.	1.0	25
288	Unusual tremor syndromes: know in order to recognise. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1191-1203.	0.9	48

#	ARTICLE	IF	CITATIONS
289	Fatigue in Parkinson's disease: report from a multidisciplinary symposium. <i>Npj Parkinson's Disease</i> , 2016, 2, .	2.5	61
290	Î±-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. <i>Trends in Neurosciences</i> , 2016, 39, 750-762.	4.2	120
291	Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 184-187.	0.8	10
292	Evolving basic, pathological and clinical concepts in PD. <i>Nature Reviews Neurology</i> , 2016, 12, 65-66.	4.9	279
293	Cortical Plasticity Induction by Pairing Subthalamic Nucleus Deep-Brain Stimulation and Primary Motor Cortical Transcranial Magnetic Stimulation in Parkinson's Disease. <i>Journal of Neuroscience</i> , 2016, 36, 396-404.	1.7	64
294	Mutation analysis of CHCHD2 in Canadian patients with familial Parkinson's disease. <i>Neurobiology of Aging</i> , 2016, 38, 217.e7-217.e8.	1.5	16
295	Orthostatic hypotension, cerebral hypoperfusion, and visuospatial deficits in Lewy body disorders. <i>Parkinsonism and Related Disorders</i> , 2016, 22, 80-86.	1.1	35
296	The role of mutations in COL6A3 in isolated dystonia. <i>Journal of Neurology</i> , 2016, 263, 730-734.	1.8	15
297	Progression of neuropsychiatric and cognitive features due to exons 2 to 5 deletion in the epsilon-sarcoglycan gene: a case report. <i>Neurocase</i> , 2016, 22, 215-219.	0.2	4
298	Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). <i>Quality of Life Research</i> , 2016, 25, 81-88.	1.5	20
299	MRI signs of multiple system atrophy preceding the clinical diagnosis: the case for an imaging-supported probable MSA diagnostic category. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 443-444.	0.9	23
300	Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0153852.	1.1	24
301	The Saskatchewan Movement Disorders Program: Commitment Pays Off. <i>Canadian Journal of Neurological Sciences</i> , 2015, 42, 70-71.	0.3	0
302	Disease-modifying strategies for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1442-1450.	2.2	188
303	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611.	2.2	1,033
304	Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EARly Parkinson's disease: the LEAP-study. <i>BMC Neurology</i> , 2015, 15, 236.	0.8	14
305	Dystonic Pseudo Foot Drop. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 295-298.	0.8	6
306	Successful treatment of functional palatal tremor: Insights into pathogenesis and management. <i>Movement Disorders</i> , 2015, 30, 875-876.	2.2	8

#	ARTICLE	IF	CITATIONS
307	Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 639-645.	0.7	49
308	Genome-wide variant by serum urate interaction in Parkinson's disease. <i>Annals of Neurology</i> , 2015, 78, 731-741.	2.8	9
309	Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015, 78, 248-257.	2.8	224
310	Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [¹¹ C]raclopride positron emission tomography imaging study. <i>Human Brain Mapping</i> , 2015, 36, 2592-2601.	1.9	17
311	Vascular Parkinsonism: Deconstructing a Syndrome. <i>Movement Disorders</i> , 2015, 30, 886-894.	2.2	88
312	Minimal change multiple system atrophy: An aggressive variant?. <i>Movement Disorders</i> , 2015, 30, 960-967.	2.2	45
313	Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0138721.	1.1	95
314	Clinical Correlations With Lewy Body Pathology in LRRK2-Related Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 100.	4.5	272
315	Helicobacter pylori infection is associated with worse severity of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 221-225.	1.1	107
316	Unfreezing of gait in patients with Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 675-677.	4.9	25
317	Colonic mucosal α -synuclein lacks specificity as a biomarker for Parkinson disease. <i>Neurology</i> , 2015, 84, 609-616.	1.5	130
318	Deep Brain Stimulation for Parkinson Disease in Elderly Individuals. <i>JAMA Neurology</i> , 2015, 72, 367.	4.5	6
319	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.	2.2	4,389
320	Placebo effect of medication cost in Parkinson disease: A randomized double-blind study. <i>Neurology</i> , 2015, 85, 742-743.	1.5	3
321	Rapid-Onset Dystonia in Parkinsonism in a Chinese Girl with a De Novo ATP1A3 c.2267G>A (p.R756H) Genetic Mutation. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 74-75.	0.8	6
322	Placebo effect of medication cost in Parkinson disease. <i>Neurology</i> , 2015, 84, 794-802.	1.5	112
323	In pursuit of prodromal Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 27-28.	4.9	2
324	Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. <i>Movement Disorders</i> , 2015, 30, 150-159.	2.2	92

#	ARTICLE	IF	CITATIONS
325	Practical guidelines for managing adults with 22q11.2 deletion syndrome. <i>Genetics in Medicine</i> , 2015, 17, 599-609.	1.1	222
326	Effects of subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease. <i>Neurology</i> , 2015, 85, 425-432.	1.5	39
327	Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa+carbidopa intestinal gel infusion. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 968-971.	1.1	23
328	Repetitive transcranial magnetic stimulation plus standardized suggestion of benefit for functional movement disorders: An open label case series. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 407-412.	1.1	22
329	Phenotype-Specific Diagnosis of Functional (Psychogenic) Movement Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 32.	2.0	108
330	Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study. <i>Biomarkers in Medicine</i> , 2015, 9, 89-97.	0.6	4
331	Parkinson's disease. <i>Lancet, The</i> , 2015, 386, 896-912.	6.3	4,079
332	Gastrointestinal dysfunction in Parkinson's disease. <i>Lancet Neurology, The</i> , 2015, 14, 625-639.	4.9	653
333	Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export. <i>Nature Genetics</i> , 2015, 47, 579-581.	9.4	237
334	Response to clozapine in a clinically identifiable subtype of schizophrenia. <i>British Journal of Psychiatry</i> , 2015, 206, 484-491.	1.7	61
335	Levodopa+carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results. <i>Movement Disorders</i> , 2015, 30, 500-509.	2.2	199
336	Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α -synucleinopathies. <i>Neurobiology of Disease</i> , 2015, 78, 162-171.	2.1	67
337	Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. <i>Movement Disorders</i> , 2015, 30, 589-592.	2.2	22
338	Restless Genital Syndrome—Reply. <i>JAMA Neurology</i> , 2015, 72, 479.	4.5	0
339	Mutation analysis of <i>CHCHD10</i> in different neurodegenerative diseases. <i>Brain</i> , 2015, 138, e380-e380.	3.7	86
340	Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. <i>Neurology</i> , 2015, 85, 1283-1292.	1.5	25
341	On the long-term outcome of orthostatic tremor. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1290-1291.	1.1	2
342	Behavioral effects of levodopa. <i>Movement Disorders</i> , 2015, 30, 90-102.	2.2	63

#	ARTICLE	IF	CITATIONS
343	Mutation analysis of patients with neurodegenerative disorders using NeuroX array. <i>Neurobiology of Aging</i> , 2015, 36, 545.e9-545.e14.	1.5	36
344	Salience network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease. <i>Annals of Neurology</i> , 2015, 77, 269-280.	2.8	93
345	Investing in the Future: Stimulation of the Medial Prefrontal Cortex Reduces Discounting of Delayed Rewards. <i>Neuropsychopharmacology</i> , 2015, 40, 546-553.	2.8	89
346	Imaging changes associated with cognitive abnormalities in Parkinson's disease. <i>Brain Structure and Function</i> , 2015, 220, 2249-2261.	1.2	41
347	Restless Genital Syndrome in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 1559.	4.5	42
348	Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome. <i>Neurology</i> , 2014, 82, 2250-2251.	1.5	56
349	Peroxisomal D-bifunctional protein deficiency. <i>Neurology</i> , 2014, 82, 963-968.	1.5	73
350	Another face of placebo: The lessebo effect in Parkinson disease. <i>Neurology</i> , 2014, 82, 1402-1409.	1.5	45
351	Reply to: Gray et al. <i>Movement Disorders</i> , 2014, 29, 1225-1226.	2.2	1
352	Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. <i>Neurology</i> , 2014, 82, 1791-1797.	1.5	147
353	'Don't delay, start today': delaying levodopa does not delay motor complications. <i>Brain</i> , 2014, 137, 2628-2630.	3.7	26
354	Global investigation and meta-analysis of the <i>C9orf72</i> (G ₄ C ₂) repeat in Parkinson disease. <i>Neurology</i> , 2014, 83, 1906-1913.	1.5	56
355	A practical approach to remote longitudinal follow-up of Parkinson's disease: The FOUND study. <i>Movement Disorders</i> , 2014, 29, 743-749.	2.2	14
356	Alimentary, my dear Watson? The challenges of enteric Î±-synuclein as a Parkinson's disease biomarker. <i>Movement Disorders</i> , 2014, 29, 444-450.	2.2	74
357	Tremor in Spinocerebellar Ataxia Type 12. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 76-78.	0.8	6
358	Subthalamic nucleus deep brain stimulation for early motor complications in Parkinson's disease—the EARLYSTIM trial: Early is not always better. <i>Movement Disorders</i> , 2014, 29, 1751-1756.	2.2	68
359	Reply: Dystonia after severe head injuries. <i>Movement Disorders</i> , 2014, 29, 578-579.	2.2	1
360	Functional/psychogenic movement disorders: Do we know what they are?. <i>Movement Disorders</i> , 2014, 29, 1696-1697.	2.2	13

#	ARTICLE	IF	CITATIONS
361	Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. <i>Genetics in Medicine</i> , 2014, 16, 644-645.	1.1	7
362	Differentiating between visual hallucination-free dementia with Lewy bodies and corticobasal syndrome on the basis of neuropsychology and perfusion single-photon emission computed tomography. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 71.	3.0	14
363	Pharmacological Treatment of Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1670.	3.8	1,097
364	Tardive dyskinesia syndromes: current concepts. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S113-S117.	1.1	81
365	Dopamineâ€‘agonists and impulsivity in Parkinson's disease: Impulsive choices vs. impulsive actions. <i>Human Brain Mapping</i> , 2014, 35, 2499-2506.	1.9	64
366	Implications of nocturnal symptoms towards the early diagnosis of Parkinsonâ€™s disease. <i>Journal of Neural Transmission</i> , 2014, 121, 49-57.	1.4	19
367	Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinsonâ€™s disease with mild cognitive impairment. <i>Brain</i> , 2014, 137, 565-575.	3.7	116
368	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 67-69.	0.8	14
369	Uncovering the role of the insula in non-motor symptoms of Parkinsonâ€™s disease. <i>Brain</i> , 2014, 137, 2143-2154.	3.7	140
370	Designing Clinical Trials for Dystonia. <i>Neurotherapeutics</i> , 2014, 11, 117-127.	2.1	15
371	The treatment of dystonic tremor: a systematic review. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 759-769.	0.9	105
372	Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease. <i>Neurotherapeutics</i> , 2014, 11, 6-23.	2.1	119
373	Neuropathological findings in chorea-acanthocytosis: new insights into mechanisms underlying parkinsonism and seizures. <i>Acta Neuropathologica</i> , 2014, 127, 613-615.	3.9	25
374	Initiating dopaminergic treatment in Parkinson's disease. <i>Lancet, The</i> , 2014, 384, 1164-1166.	6.3	17
375	Clinical heterogeneity in Progressive Supranuclear Palsy: Challenges to diagnosis, pathogenesis and future therapies. <i>Movement Disorders</i> , 2014, 29, 1707-1709.	2.2	16
376	Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 222-225.	1.1	25
377	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 454-462.	2.2	379
378	Bilateral pallidal stimulation for sargoglycan epsilon negative myoclonus. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 915-918.	1.1	17

#	ARTICLE	IF	CITATIONS
379	From psychogenic movement disorder to functional movement disorder: It's time to change the name. <i>Movement Disorders</i> , 2014, 29, 849-852.	2.2	125
380	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology</i> , The, 2014, 13, 676-685.	4.9	245
381	Tremor retraining as therapeutic strategy in psychogenic (functional) tremor. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 647-650.	1.1	36
382	Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease. <i>Human Brain Mapping</i> , 2013, 34, 1591-1604.	1.9	52
383	The prion hypothesis in Parkinson's disease: Braak to the future. <i>Acta Neuropathologica Communications</i> , 2013, 1, 2.	2.4	205
384	Clinicopathological review of pallidonigroluysian atrophy. <i>Movement Disorders</i> , 2013, 28, 274-281.	2.2	14
385	<i>Movement</i> Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments. <i>Movement Disorders</i> , 2013, 28, 1980-1986.	2.2	39
386	AFQ056 in Parkinson patients with levodopaâ€induced dyskinesia: 13â€week, randomized, doseâ€finding study. <i>Movement Disorders</i> , 2013, 28, 1838-1846.	2.2	122
387	Commentary. <i>Movement Disorders</i> , 2013, 28, 1806-1807.	2.2	1
388	Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. <i>Neurogenetics</i> , 2013, 14, 11-22.	0.7	131
389	Hemiballismâ€Hemichorea. , 2013, , 151-161.		3
390	Î±â€Synuclein oligomers and clinical implications for Parkinson disease. <i>Annals of Neurology</i> , 2013, 73, 155-169.	2.8	255
391	Efficacy and safety of T2000 in older patients with essential tremor. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 485-486.	1.1	3
392	The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 43, 151-156.	2.5	11
393	Timing of deep brain stimulation in Parkinson disease: A need for reappraisal?. <i>Annals of Neurology</i> , 2013, 73, 565-575.	2.8	67
394	Criteria for the diagnosis of corticobasal degeneration. <i>Neurology</i> , 2013, 80, 496-503.	1.5	1,445
395	Caffeine consumption and risk of dyskinesia in <sc>CALM</sc>â€<sc>PD</sc>. <i>Movement Disorders</i> , 2013, 28, 380-383.	2.2	51
396	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology</i> , The, 2013, 12, 514-524.	4.9	126

#	ARTICLE	IF	CITATIONS
397	Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the <i>TUBB4</i> gene. <i>Annals of Neurology</i> , 2013, 73, 537-545.	2.8	128
398	Phenomenology and classification of dystonia: A consensus update. <i>Movement Disorders</i> , 2013, 28, 863-873.	2.2	1,754
399	Trial designs used to study neuroprotective therapy in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 86-95.	2.2	59
400	Parkinson's disease subtypes: lost in translation?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 409-415.	0.9	181
401	Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 130-135.	0.9	103
402	Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. <i>Neurology</i> , 2013, 80, 1698-1701.	1.5	178
403	Mutations in <i>GNAL</i> cause primary torsion dystonia. <i>Nature Genetics</i> , 2013, 45, 88-92.	9.4	281
404	Voxel-Based Imaging of Translocator Protein 18Kda (TSPO) in High-Resolution PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 348-350.	2.4	10
405	Extensive intracranial calcifications in a patient with a novel polymerase gamma-1 mutation. <i>Neurology</i> , 2013, 81, 197-198.	1.5	14
406	Association Between Early-Onset Parkinson Disease and 22q11.2 Deletion Syndrome. <i>JAMA Neurology</i> , 2013, 70, 1359.	4.5	132
407	Long-term subthalamic nucleus stimulation improves sensorimotor integration and proprioception. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1020-1028.	0.9	43
408	Impact of Mild Cognitive Impairment on Health-Related Quality of Life in Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 36, 67-75.	0.7	47
409	Reply to Drs. Kurlan, Fasano, and Evans: A clinically useful definition of stereotypies. <i>Movement Disorders</i> , 2013, 28, 405-406.	2.2	0
410	Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. <i>Neurology</i> , 2013, 81, 1181-1181.	1.5	1
411	The Value of GRE, ADC and Routine MRI in Distinguishing Parkinsonian Disorders. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 389-402.	0.3	27
412	Reply to letter: multiple system atrophy-parkinsonism with slow progression and prolonged survival: A diagnostic catch. <i>Movement Disorders</i> , 2013, 28, 408-408.	2.2	0
413	Fixing the broken system of genetic locus symbols. <i>Neurology</i> , 2012, 78, 1016-1024.	1.5	70
414	Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. <i>Neurology</i> , 2012, 78, 838-838.	1.5	9

#	ARTICLE	IF	CITATIONS
415	Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. <i>Lancet Neurology</i> , The, 2012, 11, 643-650.	4.9	46
416	Psychogenic facial movement disorders: Clinical features and associated conditions. <i>Movement Disorders</i> , 2012, 27, 1544-1551.	2.2	93
417	Palliative care for advanced Parkinson disease: An interdisciplinary clinic and new scale, the ESAS-PD. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S6-S9.	1.1	102
418	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. <i>Journal of Medical Genetics</i> , 2012, 49, 721-726.	1.5	94
419	Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1125-1132.	0.9	184
420	Pardoprinox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trial. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 370-376.	1.1	32
421	Associated movement disorders in orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 725-729.	0.9	46
422	Large-scale replication and heterogeneity in Parkinson disease genetic loci. <i>Neurology</i> , 2012, 79, 659-667.	1.5	119
423	Caffeine for treatment of Parkinson disease. <i>Neurology</i> , 2012, 79, 651-658.	1.5	252
424	Investigation of C9orf72 in 4 Neurodegenerative Disorders. <i>Archives of Neurology</i> , 2012, 69, 1583.	4.9	89
425	Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1392-1397.	2.2	115
426	Reconciling Braak's model of Parkinson's disease with a prion-like spread of alpha synuclein pathology. <i>Basal Ganglia</i> , 2012, 2, 167-170.	0.3	2
427	Movement disorders in patients with diabetes mellitus. <i>Journal of the Neurological Sciences</i> , 2012, 314, 5-11.	0.3	32
428	Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study. <i>Neurobiology of Disease</i> , 2012, 48, 519-525.	2.1	123
429	Wilson Disease: Canadian Perspectives on Presentation And Outcomes from an Adult Ambulatory Setting. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 333-339.	1.8	19
430	How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. <i>Brain</i> , 2012, 135, 1860-1870.	3.7	270
431	Toward a redefinition of Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 54-60.	2.2	165
432	Premotor Parkinson's disease: Concepts and definitions. <i>Movement Disorders</i> , 2012, 27, 608-616.	2.2	140

#	ARTICLE	IF	CITATIONS
433	Extreme task specificity: Is it dystonia or another form of motor programming abnormality?. Movement Disorders, 2012, 27, 1202-1203.	2.2	2
434	Multiple system atrophy—parkinsonism with slow progression and prolonged survival: A diagnostic catch. Movement Disorders, 2012, 27, 1186-1190.	2.2	164
435	The pill questionnaire in a nondemented Parkinson's disease population. Movement Disorders, 2012, 27, 1308-1311.	2.2	15
436	Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine. Movement Disorders, 2012, 27, 326-327.	2.2	27
437	Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Movement Disorders, 2012, 27, 284-288.	2.2	68
438	Stereotypies: A critical appraisal and suggestion of a clinically useful definition. Movement Disorders, 2012, 27, 179-185.	2.2	93
439	Acquired neurosyphilis presenting as movement disorders. Movement Disorders, 2012, 27, 690-695.	2.2	45
440	A case of neurosyphilis presenting with myoclonus, cerebellar ataxia, and speech disturbance. Movement Disorders, 2012, 27, 794-794.	2.2	14
441	Stem cell therapy for Parkinson's disease. Annals of Neurology, 2012, 71, 283-283.	2.8	4
442	Other Movement Disorders. , 2012, , 2333-2342.		0
443	Psychogenic dystonia. , 2012, , 307-319.		0
444	Cannabinoid, CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled trial. Basal Ganglia, 2011, 1, 91-95.	0.3	33
445	Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. Neurobiology of Aging, 2011, 32, 2108.e1-2108.e5.	1.5	23
446	Development of a Non-Motor Fluctuation Assessment Instrument for Parkinson Disease. Parkinson's Disease, 2011, 2011, 1-13.	0.6	30
447	Measuring quality of life in progressive supranuclear palsy. , 2011, , 52-59.		1
448	Translational Research in Neurology and Neuroscience 2011. Archives of Neurology, 2011, 68, 709-16.	4.9	12
449	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurology, The, 2011, 10, 415-423.	4.9	192
450	Deep brain stimulation for dystonia. Movement Disorders, 2011, 26, S3-4.	2.2	3

#	ARTICLE	IF	CITATIONS
451	Thalamic neuronal and EMG activity in psychogenic dystonia compared with organic dystonia. <i>Movement Disorders</i> , 2011, 26, 1348-1352.	2.2	18
452	Psychogenic movement disorders: Past developments, current status, and future directions. <i>Movement Disorders</i> , 2011, 26, 1175-1186.	2.2	42
453	Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. <i>Movement Disorders</i> , 2011, 26, 608-613.	2.2	20
454	Pardoprinox in early Parkinson's disease: Results from 2 large, randomized double-blind trials. <i>Movement Disorders</i> , 2011, 26, 1464-1476.	2.2	38
455	A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials. <i>Movement Disorders</i> , 2011, 26, 775-783.	2.2	128
456	Tongue control for swallowing in Parkinson's disease: Effects of age, rate, and stimulus consistency. <i>Movement Disorders</i> , 2011, 26, 1725-1729.	2.2	25
457	Crossing the borders between neurology and psychiatry in functional neurological disorders. <i>Movement Disorders</i> , 2011, 26, 1373-1374.	2.2	1
458	Expanding the phenomenology of benign hereditary chorea: Evolution from chorea to myoclonus and dystonia. <i>Movement Disorders</i> , 2011, 26, 2296-2297.	2.2	15
459	Early-onset tardive dyskinesia in a neuroleptic-naïve patient exposed to low-dose quetiapine. <i>Movement Disorders</i> , 2011, 26, 2297-2298.	2.2	7
460	The curious case of phenocopies in families with genetic Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1793-1802.	2.2	40
461	Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study. <i>Movement Disorders</i> , 2011, 26, 2427-2431.	2.2	44
462	Impulse control disorders in parkinson disease: A multicenter case-control study. <i>Annals of Neurology</i> , 2011, 69, 986-996.	2.8	361
463	Movement Disorders on YouTube – Caveat Spectator. <i>New England Journal of Medicine</i> , 2011, 365, 1160-1161.	13.9	77
464	Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. <i>Journal of Neurosurgery</i> , 2011, 114, 1428-1431.	0.9	20
465	Ten-Year Outcome of Subthalamic Stimulation in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 1550.	4.9	397
466	Dopamine Agonists vs Levodopa in Impulse Control Disorders – Reply. <i>Archives of Neurology</i> , 2011, 68, 544.	4.9	0
467	Phenotype in parkinsonian and nonparkinsonian <i>LRRK2</i> G2019S mutation carriers. <i>Neurology</i> , 2011, 77, 325-333.	1.5	163
468	Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson's disease. <i>Brain</i> , 2011, 134, 2096-2105.	3.7	83

#	ARTICLE	IF	CITATIONS
469	The psychogenic toe signs. <i>Neurology</i> , 2011, 77, 508-509.	1.5	16
470	Surgical correction of kyphosis in patients with camptocormia due to Parkinson's disease: a retrospective evaluation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 364-368.	0.9	40
471	Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease. <i>Journal of Human Genetics</i> , 2011, 56, 671-675.	1.1	10
472	Clinical Vignettes in Parkinson's Disease: A Collection of Unusual Medication-Induced Hallucinations, Delusions, and Compulsive Behaviours. <i>International Journal of Neuroscience</i> , 2011, 121, 472-476.	0.8	6
473	A Survey on the Impact of the Menstrual Cycle on Movement Disorders Severity. <i>Canadian Journal of Neurological Sciences</i> , 2010, 37, 478-481.	0.3	6
474	Event-related desynchronization of motor cortical oscillations in patients with multiple system atrophy. <i>Experimental Brain Research</i> , 2010, 206, 1-13.	0.7	9
475	Extrastriatal dopaminergic dysfunction in tourette syndrome. <i>Annals of Neurology</i> , 2010, 67, 170-181.	2.8	92
476	Dystonia in complex regional pain syndrome type I. <i>Annals of Neurology</i> , 2010, 67, 412-414.	2.8	24
477	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDEâ€”PD study. <i>Annals of Neurology</i> , 2010, 68, 18-27.	2.8	330
478	Amantadine use associated with impulse control disorders in Parkinson disease in crossâ€”sectional study. <i>Annals of Neurology</i> , 2010, 68, 963-968.	2.8	132
479	Involvement of the cerebellothalamocortical pathway in Parkinson disease. <i>Annals of Neurology</i> , 2010, 68, 816-824.	2.8	117
480	Longâ€”term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 578-586.	2.2	382
481	The nonmotor symptoms of Parkinson's diseaseâ€”An overview. <i>Movement Disorders</i> , 2010, 25, S123-30.	2.2	130
482	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. <i>Movement Disorders</i> , 2010, 25, 1077-1081.	2.2	106
483	Neuronal intranuclear inclusion disease: Two cases of dopaâ€”responsive juvenile parkinsonism with drugâ€”induced dyskinesia. <i>Movement Disorders</i> , 2010, 25, 1274-1279.	2.2	25
484	Effect of movement frequency on repetitive finger movements in patients with Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 252-252.	2.2	3
485	Doubleâ€”blind study of pardoprinox, a new partial dopamine agonist, in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 738-746.	2.2	32
486	Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1801-1808.	2.2	23

#	ARTICLE	IF	CITATIONS
487	Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 961-962.	2.2	8
488	Characteristic head drops and axial extension in advanced choreaâ€acanthocytosis. <i>Movement Disorders</i> , 2010, 25, 1487-1491.	2.2	54
489	The grasp reflex: A symptom in need of treatment. <i>Movement Disorders</i> , 2010, 25, 2479-2485.	2.2	9
490	Definition and classification of hyperkinetic movements in childhood. <i>Movement Disorders</i> , 2010, 25, 1538-1549.	2.2	374
491	Drug-induced cranial myoclonus. <i>Movement Disorders</i> , 2010, 25, 2264-2265.	2.2	14
492	Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBSâ€PD). <i>Movement Disorders</i> , 2010, 25, 1530-1537.	2.2	20
493	Longâ€term effect of unilateral pallidotomy on levodopaâ€induced dyskinesia. <i>Movement Disorders</i> , 2010, 25, 1496-1498.	2.2	22
494	Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. <i>Nature Medicine</i> , 2010, 16, 1223-1226.	15.2	83
495	The Nature and Time Course of Cortical Activation Following Subthalamic Stimulation in Parkinson's Disease. <i>Cerebral Cortex</i> , 2010, 20, 1926-1936.	1.6	125
496	Impulse Control Disorders in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 589-95.	4.9	1,244
497	Therapy of the Motor Features of Parkinson's Disease. <i>Blue Books of Neurology</i> , 2010, 34, 252-272.	0.1	1
498	Patient perception of dyskinesia in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1112-1115.	0.9	45
499	Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. <i>Neurology</i> , 2010, 75, 1711-1716.	1.5	191
500	Oxidative stress alters the regulatory control of p66Shc and Akt in PINK1 deficient cells. <i>Biochemical and Biophysical Research Communications</i> , 2010, 399, 331-335.	1.0	19
501	LRRK2 and Parkin mutations in a family with parkinsonismâ€”Lack of genotypeâ€phenotype correlation. <i>Neurobiology of Aging</i> , 2010, 31, 721-722.	1.5	9
502	Impaired presynaptic inhibition in the motor cortex in Parkinson disease. <i>Neurology</i> , 2009, 72, 842-849.	1.5	68
503	Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease. <i>Archives of Neurology</i> , 2009, 66, 1460.	4.9	326
504	When and how should treatment be started in Parkinson disease?. <i>Neurology</i> , 2009, 72, S39-43.	1.5	52

#	ARTICLE	IF	CITATIONS
505	A new sensitive imaging biomarker for Parkinson disease?. <i>Neurology</i> , 2009, 72, 1374-1375.	1.5	15
506	Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [¹¹ C] raclopride PET study. <i>Brain</i> , 2009, 132, 1376-1385.	3.7	475
507	Reply: Parkinson's disease, DBS and suicide: a role for serotonin?. <i>Brain</i> , 2009, 132, e127-e127.	3.7	5
508	Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. <i>Neuropsychopharmacology</i> , 2009, 34, 2758-2766.	2.8	140
509	Overview of the Extranigral Aspects of Parkinson Disease. <i>Archives of Neurology</i> , 2009, 66, 167-72.	4.9	172
510	Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients with Advanced Parkinson's Disease. <i>European Neurology</i> , 2009, 62, 40-48.	0.6	27
511	Selective enhancement of rapid eye movement sleep by deep brain stimulation of the human pons. <i>Annals of Neurology</i> , 2009, 66, 110-114.	2.8	106
512	Dopaminergic transplantation for parkinson's disease: Current status and future prospects. <i>Annals of Neurology</i> , 2009, 66, 591-596.	2.8	80
513	Stimulation of the subthalamic nucleus and impulsivity: Release your horses. <i>Annals of Neurology</i> , 2009, 66, 817-824.	2.8	225
514	Cerebral blood flow changes induced by pedunculo-pontine nucleus stimulation in patients with advanced Parkinson's disease: A [¹⁵ O] H ₂ O PET study. <i>Human Brain Mapping</i> , 2009, 30, 3901-3909.	1.9	99
515	Impairments of speed and amplitude of movement in Parkinson's disease: A pilot study. <i>Movement Disorders</i> , 2009, 24, 1001-1008.	2.2	104
516	Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. <i>Movement Disorders</i> , 2009, 24, 1366-1374.	2.2	138
517	Alien hand syndrome and dystonia in a pediatric patient. <i>Movement Disorders</i> , 2009, 24, 1557-1559.	2.2	6
518	Hereditary parkinsonism: Parkinson disease look-alikes? An algorithm for clinicians to <i>PARK</i> genes and beyond. <i>Movement Disorders</i> , 2009, 24, 2042-2058.	2.2	62
519	A longitudinal program for biomarker development in Parkinson's disease: A feasibility study. <i>Movement Disorders</i> , 2009, 24, 2081-2090.	2.2	48
520	<i>ATP13A2</i> variants in early-onset Parkinson's disease patients and controls. <i>Movement Disorders</i> , 2009, 24, 2104-2111.	2.2	62
521	Rasagiline-induced spontaneous ejaculation. <i>Movement Disorders</i> , 2009, 24, 2160-2161.	2.2	9
522	A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. <i>Movement Disorders</i> , 2009, 24, 2370-2378.	2.2	11

#	ARTICLE	IF	CITATIONS
523	Understanding disability in Tourette syndrome. <i>Developmental Medicine and Child Neurology</i> , 2009, 51, 468-472.	1.1	61
524	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. <i>European Journal of Neurology</i> , 2009, 16, 297-309.	1.7	170
525	Myoclonus in complex regional pain syndrome. <i>Movement Disorders</i> , 2009, 24, 314-316.	2.2	22
526	Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2009, 361, 1651-1661.	13.9	1,747
527	A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2009, 361, 1268-1278.	13.9	830
528	Prenatal and Perinatal Morbidity in Children with Tourette Syndrome and Attention-Deficit Hyperactivity Disorder. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2009, 30, 115-121.	0.6	44
529	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2009, 22, 430-436.	1.8	303
530	Polymyoclonus, Laryngospasm, and Cerebellar Ataxia Associated With Adenocarcinoma and Multiple Neural Cation Channel Autoantibodies. <i>Archives of Neurology</i> , 2009, 66, 1285-7.	4.9	2
531	Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. <i>Neuropsychopharmacology</i> , 2009, 34, 2758-66.	2.8	83
532	Surgery for Movement Disorders: An Overview. , 2009, , 1443-1466.		0
533	The spectrum of orolingual tremor—A proposed classification system. <i>Movement Disorders</i> , 2008, 23, 159-167.	2.2	46
534	Phenotypic spectrum and sex effects in eleven myoclonus-dystonia families with sarcoglycan mutations. <i>Movement Disorders</i> , 2008, 23, 588-592.	2.2	66
535	The G2019S <i>LRRK2</i> mutation in Brazilian patients with Parkinson's disease: Phenotype in monozygotic twins. <i>Movement Disorders</i> , 2008, 23, 290-294.	2.2	20
536	A comparison of the mini mental state exam to the montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 297-299.	2.2	266
537	Predictors of deterioration in health-related quality of life in Parkinson's disease: Results from the DATATOP trial. <i>Movement Disorders</i> , 2008, 23, 653-659.	2.2	122
538	Large deletions account for an increasing number of mutations in <i>SGCE</i> . <i>Movement Disorders</i> , 2008, 23, 456-460.	2.2	27
539	Levodopa-related motor complications-Phenomenology. <i>Movement Disorders</i> , 2008, 23, S509-S514.	2.2	93
540	Reply: The variability of levodopa response in Parkinson's disease: Is sensitization reversible?. <i>Movement Disorders</i> , 2008, 23, 925-925.	2.2	0

#	ARTICLE	IF	CITATIONS
541	rCBF changes associated with PPN stimulation in a patient with Parkinson's disease: A PET study. <i>Movement Disorders</i> , 2008, 23, 1051-1054.	2.2	56
542	Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease?. <i>Movement Disorders</i> , 2008, 23, 1689-1695.	2.2	85
543	A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics. <i>Movement Disorders</i> , 2008, 23, 2194-2201.	2.2	162
544	Electrophysiological features of myoclonus-dystonia. <i>Movement Disorders</i> , 2008, 23, 2055-2061.	2.2	42
545	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170.	2.2	4,796
546	Myoclonus-dystonia: significance of large <i>SCCE</i> deletions. <i>Human Mutation</i> , 2008, 29, 331-332.	1.1	138
547	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. <i>Lancet Neurology</i> , The, 2008, 7, 583-590.	4.9	1,340
548	Non-dopaminergic treatments in development for Parkinson's disease. <i>Lancet Neurology</i> , The, 2008, 7, 927-938.	4.9	106
549	A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. <i>Brain</i> , 2008, 131, 2720-2728.	3.7	460
550	Bilateral subthalamic stimulation in <i>Parkin</i> and <i>PINK1</i> parkinsonism. <i>Neurology</i> , 2008, 70, 1186-1191.	1.5	66
551	Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 716.	4.9	295
552	Invited Article: Changing concepts in Parkinson disease. <i>Neurology</i> , 2008, 70, 1996-2003.	1.5	73
553	MIXED LINEAGE KINASE INHIBITOR CEP-1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE. <i>Neurology</i> , 2008, 71, 462-463.	1.5	51
554	Impact of standard of care for psychosis in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1413-1415.	0.9	24
555	Pergolide Associated Cardiac Valvulopathy Based on Ontario Administrative Data. <i>Canadian Journal of Neurological Sciences</i> , 2008, 35, 173-178.	0.3	11
556	Treatment of Motor Complications in Advanced Parkinson's Disease. , 2008, , 71-90.		0
557	Reduced Intracortical and Interhemispheric Inhibitions in Corticobasal Syndrome. <i>Journal of Clinical Neurophysiology</i> , 2008, 25, 304-312.	0.9	24
558	PATIENT MANAGEMENT PROBLEM. CONTINUUM Lifelong Learning in Neurology, 2008, 14, 182-193.	0.4	0

#	ARTICLE	IF	CITATIONS
559	Movement Disorders: Diagnosis and Assessment. , 2008, , 293-325.		6
560	Diagnosing psychogenic movement disordersâ€”which criteria should be used in clinical practice?. Nature Clinical Practice Neurology, 2007, 3, 134-135.	2.7	16
561	FIXED DYSTONIA UNRESPONSIVE TO PALLIDAL STIMULATION IMPROVED BY MOTOR CORTEX STIMULATION. Neurology, 2007, 69, 1062-1063.	1.5	7
562	Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia. Neurology, 2007, 68, 1782-1789.	1.5	154
563	Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. Neurology, 2007, 68, 457-459.	1.5	223
564	Factors Associated With Dopaminergic Drugâ€”Related Pathological Gambling in Parkinson Disease. Archives of Neurology, 2007, 64, 212.	4.9	322
565	VITAMINS AND ENTACAPONE IN LEVODOPA-INDUCED HYPERHOMOCYSTEINEMIA: A RANDOMIZED CONTROLLED STUDY. Neurology, 2007, 68, 1440-1441.	1.5	16
566	The progression of Parkinson disease. Neurology, 2007, 68, 948-952.	1.5	109
567	Involvement of the Basal Ganglia and Cerebellar Motor Pathways in the Preparation of Self-Initiated and Externally Triggered Movements in Humans. Journal of Neuroscience, 2007, 27, 6029-6036.	1.7	65
568	Isolated diaphragmatic tremor. Neurology, 2007, 69, 689-692.	1.5	25
569	Subthalamic nucleus stimulation modulates afferent inhibition in Parkinson disease. Neurology, 2007, 68, 356-363.	1.5	62
570	Manganese-Induced Parkinsonism Associated With Methcathinone (Ephedrone) Abuse. Archives of Neurology, 2007, 64, 886.	4.9	95
571	Low-frequency repetitive transcranial magnetic stimulation for treatment of levodopa-induced dyskinesias. Neurology, 2007, 68, 704-705.	1.5	54
572	Neuronal Firing Rates and Patterns in the Globus Pallidus Internus of Patients With Cervical Dystonia Differ From Those With Parkinson's Disease. Journal of Neurophysiology, 2007, 98, 720-729.	0.9	129
573	An update on movement disorders: exciting developments but new obstacles. Current Opinion in Neurology, 2007, 20, 432-433.	1.8	0
574	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. Journal of Neuropathology and Experimental Neurology, 2007, 66, 251-257.	0.9	104
575	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II. Journal of Neuropathology and Experimental Neurology, 2007, 66, 329-336.	0.9	41
576	Clinical Practice Regarding Dopamine-Agonist Use and Driving in Parkinson's Disease. Canadian Journal of Neurological Sciences, 2007, 34, 438-442.	0.3	2

#	ARTICLE	IF	CITATIONS
577	Changes in cortical and pallidal oscillatory activity during the execution of a sensory trick in patients with cervical dystonia. <i>Experimental Neurology</i> , 2007, 204, 845-848.	2.0	53
578	The many faces of corticobasal degeneration. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S336-S340.	1.1	91
579	Motor and non-motor fluctuations. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 84, 157-184.	1.0	6
580	Characterization of REM-Sleep Associated Ponto-Geniculo-Occipital Waves in the Human Pons. <i>Sleep</i> , 2007, 30, 823-827.	0.6	95
581	Antidepressants and psychosis in Parkinson disease: a case series. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 601-604.	1.3	21
582	Antipsychotic use in older adults with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 319-323.	2.2	26
583	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007, 22, 41-47.	2.2	1,097
584	Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: Differential effects on bradykinesia. <i>Movement Disorders</i> , 2007, 22, 328-333.	2.2	37
585	Is there seasonal variation in risk of Parkinson's disease?. <i>Movement Disorders</i> , 2007, 22, 1097-1101.	2.2	11
586	Gait abnormalities in psychogenic movement disorders. <i>Movement Disorders</i> , 2007, 22, 395-399.	2.2	125
587	Punding prevalence in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1179-1181.	2.2	125
588	Rapid and reliable detection of exon rearrangements in various movement disorders genes by multiplex ligation-dependent probe amplification. <i>Movement Disorders</i> , 2007, 22, 1708-1714.	2.2	16
589	Interhemispheric and ipsilateral connections in Parkinson's disease: Relation to mirror movements. <i>Movement Disorders</i> , 2007, 22, 813-821.	2.2	97
590	Refinement of the DYT15 locus in myoclonus dystonia. <i>Movement Disorders</i> , 2007, 22, 888-892.	2.2	41
591	Orthostatic tremor in progressive supranuclear palsy. <i>Movement Disorders</i> , 2007, 22, 1192-1194.	2.2	17
592	Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 990-997.	2.2	106
593	Sustained relief of dystonia following cessation of deep brain stimulation. <i>Movement Disorders</i> , 2007, 22, 1958-1962.	2.2	59
594	Benign hereditary chorea revisited: A journey to understanding. <i>Movement Disorders</i> , 2007, 22, 2297-2305.	2.2	50

#	ARTICLE	IF	CITATIONS
595	Subdural motor cortex stimulation in Parkinson's disease does not modify movement-related rCBF pattern. <i>Movement Disorders</i> , 2007, 22, 2113-2116.	2.2	33
596	Reversible dopamine agonist induced anterocollis in a multiple system atrophy patient. <i>Movement Disorders</i> , 2007, 22, 2292-2293.	2.2	11
597	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , 2007, 22, 2409-2417.	2.2	221
598	GDNF in Parkinson's disease: The perils of post-hoc power. <i>Journal of Neuroscience Methods</i> , 2007, 163, 193-196.	1.3	13
599	Deciphering the role of heterozygous mutations in genes associated with parkinsonism. <i>Lancet Neurology</i> , The, 2007, 6, 652-662.	4.9	290
600	Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2006, 66, 845-851.	1.5	371
601	Criteria for deep-brain stimulation in Parkinson's disease: review and analysis. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1695-1705.	1.4	71
602	Cardiac Valvulopathy Associated with Pergolide Use. <i>Canadian Journal of Neurological Sciences</i> , 2006, 33, 27-33.	0.3	26
603	Prospective prevalence of pathologic gambling and medication association in Parkinson disease. <i>Neurology</i> , 2006, 66, 1750-1752.	1.5	316
604	Contemporary assessment and pharmacotherapy of Tourette syndrome. <i>NeuroRx</i> , 2006, 3, 192-206.	6.0	273
605	GDNF in treatment of Parkinson's disease: response to editorial. <i>Lancet Neurology</i> , The, 2006, 5, 200-202.	4.9	35
606	Neuroprotection in Parkinson's disease: and now for something completely different?. <i>Lancet Neurology</i> , The, 2006, 5, 990-991.	4.9	20
607	Homozygous and heterozygous PINK1 mutations: Considerations for diagnosis and care of Parkinson's disease patients. <i>Movement Disorders</i> , 2006, 21, 875-879.	2.2	31
608	Crossroads in GDNF therapy for Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 136-141.	2.2	163
609	Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure. <i>Movement Disorders</i> , 2006, 21, 1578-1594.	2.2	99
610	Deep brain stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, S168-S170.	2.2	62
611	Deep brain stimulation: Preoperative issues. <i>Movement Disorders</i> , 2006, 21, S171-S196.	2.2	260
612	Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes. <i>Movement Disorders</i> , 2006, 21, S290-S304.	2.2	811

#	ARTICLE	IF	CITATIONS
613	Development of dyskinesias in a 5-year trial of ropinirole and L -dopa. <i>Movement Disorders</i> , 2006, 21, 1844-1850.	2.2	145
614	Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. <i>Movement Disorders</i> , 2006, 21, 1941-1946.	2.2	245
615	Rapidly progressive sporadic dentatorubral pallidoluysian atrophy with intracytoplasmic inclusions and no CAG repeat expansion. <i>Movement Disorders</i> , 2006, 21, 2251-2254.	2.2	11
616	Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. <i>Annals of Neurology</i> , 2006, 59, 459-466.	2.8	890
617	Interface between tauopathies and synucleinopathies: A tale of two proteins. <i>Annals of Neurology</i> , 2006, 59, 449-458.	2.8	240
618	Cortical and spinal abnormalities in psychogenic dystonia. <i>Annals of Neurology</i> , 2006, 59, 825-834.	2.8	195
619	The proteasomal inhibition model of Parkinson's disease: "Boon or bust"? <i>Annals of Neurology</i> , 2006, 60, 158-161.	2.8	41
620	Subthalamic Nucleus Stimulation. <i>Archives of Neurology</i> , 2006, 63, 1266.	4.9	70
621	Childhood Onset in Familial Prion Disease With a Novel Mutation in the PRNP Gene. <i>Archives of Neurology</i> , 2006, 63, 1016.	4.9	20
622	The "essentials"™ of essential palatal tremor: a reappraisal of the nosology. <i>Brain</i> , 2006, 129, 832-840.	3.7	180
623	Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. <i>Neurology</i> , 2006, 67, 1254-1257.	1.5	416
624	Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: A randomized controlled study. <i>Neurology</i> , 2006, 66, 1941-1943.	1.5	61
625	A case of a psychogenic "jumpy stump". <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1101-1101.	0.9	16
626	Mirror movements in Parkinson's disease: effect of dopaminergic drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1194-1195.	0.9	21
627	Can visual hallucinations be used as a diagnostic factor in Parkinson's disease?. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 246-247.	2.7	0
628	Beta Oscillatory Activity in the Subthalamic Nucleus and Its Relation to Dopaminergic Response in Parkinson's Disease. <i>Journal of Neurophysiology</i> , 2006, 96, 3248-3256.	0.9	520
629	Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. <i>Brain</i> , 2006, 129, 1059-1069.	3.7	286
630	Subthalamic Nucleus Stimulation: Improvements in Outcome With Reprogramming. <i>Archives of Neurology</i> , 2006, 63, 1266-1272.	4.9	101

#	ARTICLE	IF	CITATIONS
631	Psychogenic Dystonia. <i>Medical Psychiatry</i> , 2006, , 277-288.	0.2	0
632	Contemporary assessment and pharmacotherapy of Tourette syndrome. <i>Neurotherapeutics</i> , 2006, 3, 192-206.	2.1	0
633	Evolution of Parkinson's Disease and Treatment Requirements: What New Treatments are Needed and the Role of Striatal Grafting. , 2006, , 50-64.		0
634	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2005, 18, 399-404.	1.8	46
635	Progress in Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2005, 32, 277-286.	0.3	4
636	Survival in Parkinson disease. <i>Neurology</i> , 2005, 64, 87-93.	1.5	139
637	Analysis of the glucocerebrosidase gene in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 367-370.	2.2	107
638	Pallidal deep brain stimulation influences both reflexive and voluntary saccades in Huntington's disease. <i>Movement Disorders</i> , 2005, 20, 371-377.	2.2	27
639	Does severity of Parkinson's disease vary according to season?. <i>Movement Disorders</i> , 2005, 20, 476-479.	2.2	12
640	Treatment of progressive supranuclear palsy and corticobasal degeneration. <i>Movement Disorders</i> , 2005, 20, S83-S91.	2.2	50
641	Normalization of voice in spasmodic dysphonia during transient global amnesia. <i>Movement Disorders</i> , 2005, 20, 1228-1229.	2.2	0
642	Alterations of striatal neurons in benign hereditary chorea. <i>Movement Disorders</i> , 2005, 20, 1353-1357.	2.2	63
643	Firing rates of pallidal neurons are similar in Huntington's and Parkinson's disease patients. <i>Experimental Brain Research</i> , 2005, 166, 230-236.	0.7	72
644	Identification of a VPS13A founder mutation in French Canadian families with chorea-acanthocytosis. <i>Neurogenetics</i> , 2005, 6, 151-158.	0.7	36
645	Selected genetically engineered models relevant to human neurodegenerative disease. , 2005, , 176-195.		1
646	Structural and functional magnetic resonance imaging in neurodegenerative diseases. , 2005, , 253-289.		2
647	Corticobasal degeneration. , 2005, , 682-696.		0
648	Neurophysiology of Parkinson's disease, levodopa-induced dyskinesias, dystonia, Huntington's disease and myoclonus. , 2005, , 227-250.		0

#	ARTICLE	IF	CITATIONS
649	Current and potential treatments of Parkinson's disease. , 2005, , 612-622.		0
650	Multiple system atrophy. , 2005, , 623-662.		2
651	Changes in cortical excitability with thalamic deep brain stimulation. Neurology, 2005, 64, 1913-1919.	1.5	43
652	A writing device improves writing in primary writing tremor. Neurology, 2005, 64, 1648-1650.	1.5	45
653	Psychiatric symptoms in patients with Parkinson disease presenting for deep brain stimulation surgery. Journal of Neurosurgery, 2005, 103, 246-251.	0.9	50
654	Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain, 2005, 128, 2240-2249.	3.7	963
655	Mirror movements in parkinsonism: evaluation of a new clinical sign. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1355-1359.	0.9	96
656	LRRK2 gene in Parkinson disease: Mutation analysis and case control association study. Neurology, 2005, 65, 696-700.	1.5	160
657	Apraxia in movement disorders. Brain, 2005, 128, 1480-1497.	3.7	228
658	Parkinsonian Tremor. Neurological Disease and Therapy, 2005, , 195-220.	0.0	8
659	Antidepressant Treatment Outcomes of Psychogenic Movement Disorder. Journal of Clinical Psychiatry, 2005, 66, 1529-1534.	1.1	125
660	Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease. Archives of Neurology, 2004, 61, 1044-53.	4.9	446
661	The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. Human Molecular Genetics, 2004, 13, 3161-3170.	1.4	196
662	Analysis of the PINK1 Gene in a Large Cohort of Cases With Parkinson Disease. Archives of Neurology, 2004, 61, 1898-904.	4.9	162
663	Clinical Findings in a Large Family With a Parkin Ex3 ⁺ 40 Mutation. Archives of Neurology, 2004, 61, 701.	4.9	24
664	Progressive ataxia and palatal tremor (PAPT): Clinical and MRI assessment with review of palatal tremors. Brain, 2004, 127, 1252-1268.	3.7	134
665	Levodopa and the Progression of Parkinson's Disease. New England Journal of Medicine, 2004, 351, 2498-2508.	13.9	1,649
666	Single Pulse Stimulation of the Human Subthalamic Nucleus Facilitates the Motor Cortex at Short Intervals. Journal of Neurophysiology, 2004, 92, 1937-1943.	0.9	55

#	ARTICLE	IF	CITATIONS
667	Involvement of human thalamus in the preparation of self-paced movement. <i>Brain</i> , 2004, 127, 2717-2731.	3.7	111
668	Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. <i>Neurology</i> , 2004, 63, 2410-2412.	1.5	127
669	Thalamic deep brain stimulation activates the cerebellothalamocortical pathway. <i>Neurology</i> , 2004, 63, 907-909.	1.5	65
670	Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. <i>Lancet Neurology</i> , The, 2004, 3, 309-316.	4.9	302
671	Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. <i>Annals of Neurology</i> , 2004, 55, 761-765.	2.8	95
672	Bilateral globus pallidus stimulation for Huntington's disease. <i>Annals of Neurology</i> , 2004, 56, 290-294.	2.8	207
673	Chorein detection for the diagnosis of chorea-acanthocytosis. <i>Annals of Neurology</i> , 2004, 56, 299-302.	2.8	186
674	Gestes antagonistes in psychogenic dystonia. <i>Movement Disorders</i> , 2004, 19, 331-332.	2.2	36
675	Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations. <i>Movement Disorders</i> , 2004, 19, 22-28.	2.2	89
676	Sporadic case of dentatorubral pallidoluysian atrophy with no CAG repeat expansion and no intranuclear inclusions. <i>Movement Disorders</i> , 2004, 19, 580-583.	2.2	9
677	Rapidly progressive behavioral changes and parkinsonism in a 68-year-old man. <i>Movement Disorders</i> , 2004, 19, 534-543.	2.2	4
678	Dystonia as a presenting sign of spinocerebellar ataxia type 1. <i>Movement Disorders</i> , 2004, 19, 586-587.	2.2	36
679	Farewell from the outgoing editors. <i>Movement Disorders</i> , 2004, 19, 2-2.	2.2	8
680	Voluntary control and a wider clinical spectrum of essential palatal tremor. <i>Movement Disorders</i> , 2004, 19, 717-719.	2.2	21
681	Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: A case report. <i>Movement Disorders</i> , 2004, 19, 969-972.	2.2	84
682	Presentation of Creutzfeldt-Jakob disease as acute corticobasal degeneration syndrome. <i>Movement Disorders</i> , 2004, 19, 948-949.	2.2	42
683	Subthalamic nucleus deep brain stimulation for parkinson's disease after successful pallidotomy: Clinical and electrophysiological observations. <i>Movement Disorders</i> , 2004, 19, 1209-1214.	2.2	46
684	Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. <i>Movement Disorders</i> , 2004, 19, 656-662.	2.2	240

#	ARTICLE	IF	CITATIONS
685	Distribution, type, and origin of Parkin mutations: Review and case studies. <i>Movement Disorders</i> , 2004, 19, 1146-1157.	2.2	219
686	Neuronal activity in the globus pallidus of multiple system atrophy patients. <i>Movement Disorders</i> , 2004, 19, 1485-1492.	2.2	10
687	Severe evening dyskinesias in advanced Parkinson's disease: Clinical description, relation to plasma levodopa, and treatment. <i>Movement Disorders</i> , 2004, 9, 173-177.	2.2	17
688	Withdrawal akathisia: Case reports and a proposed classification of chronic akathisia. <i>Movement Disorders</i> , 2004, 9, 188-192.	2.2	37
689	Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 985-993.	1.4	16
690	The perioperative management of Parkinson's disease revisited. <i>Neurologic Clinics</i> , 2004, 22, 367-377.	0.8	30
691	Genetic association study of PINK1 coding polymorphisms in Parkinson's disease. <i>Neuroscience Letters</i> , 2004, 372, 226-229.	1.0	31
692	<i>DJ-1 (PARK7)</i> mutations are less frequent than <i>Parkin (PARK2)</i> mutations in early-onset Parkinson disease. <i>Neurology</i> , 2004, 62, 389-394.	1.5	188
693	Primary Dystonia Is More Responsive than Secondary Dystonia to Pallidal Interventions: Outcome after Pallidotomy or Pallidal Deep Brain Stimulation. <i>Neurosurgery</i> , 2004, 54, 613-621.	0.6	278
694	Pallidal Deep Brain Stimulation in Cervical Dystonia: Clinical Outcome in Four Cases. <i>Canadian Journal of Neurological Sciences</i> , 2004, 31, 328-332.	0.3	75
695	Insights into brain function through the examination of art: the influence of neurodegenerative diseases. <i>NeuroReport</i> , 2004, 15, 933-937.	0.6	8
696	Antidepressants in the Treatment of Psychosis With Comorbid Depression in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2004, 27, 90-92.	0.2	30
697	Predictors of Impaired Daytime Sleep and Wakefulness in Patients With Parkinson Disease Treated With Older (Ergot) vs Newer (Nonergot) Dopamine Agonists. <i>Archives of Neurology</i> , 2004, 61, 97.	4.9	174
698	Hemiballism: revisiting a classic disorder. <i>Lancet Neurology</i> , The, 2003, 2, 661-668.	4.9	217
699	Acute effect of transcutaneous electrical nerve stimulation on tremor. <i>Movement Disorders</i> , 2003, 18, 191-194.	2.2	12
700	Neurodegenerative disease and the evolution of art: The effects of presumed corticobasal degeneration in a professional artist. <i>Movement Disorders</i> , 2003, 18, 294-302.	2.2	29
701	Corticobasal degeneration syndrome with basal ganglia calcification: Fahr's disease as a corticobasal look-alike?. <i>Movement Disorders</i> , 2003, 18, 351-352.	2.2	2
702	Unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin. <i>Movement Disorders</i> , 2003, 18, 942-948.	2.2	17

#	ARTICLE	IF	CITATIONS
703	Dopa-responsive dystonia presenting with prominent isolated bilateral resting leg tremor: Evidence for a role of parkin?. <i>Movement Disorders</i> , 2003, 18, 1070-1072.	2.2	7
704	Corticobasal degeneration: Selected developments. <i>Movement Disorders</i> , 2003, 18, 51-56.	2.2	40
705	Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: A functional MRI case study. <i>Movement Disorders</i> , 2003, 18, 1508-1516.	2.2	191
706	Posttraumatic painful torticollis. <i>Movement Disorders</i> , 2003, 18, 1482-1491.	2.2	81
707	Pure cerebello-olivary degeneration of Marie, Foix, and Alajouanine presenting with progressive cerebellar ataxia, cognitive decline, and chorea. <i>Movement Disorders</i> , 2003, 18, 1550-1554.	2.2	12
708	Pallidal neuronal activity: Implications for models of dystonia. <i>Annals of Neurology</i> , 2003, 53, 480-488.	2.8	246
709	Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. <i>Annals of Neurology</i> , 2003, 54, S15-S19.	2.8	496
710	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. <i>Annals of Neurology</i> , 2003, 54, 93-101.	2.8	820
711	Benign hereditary chorea: Clinical, genetic, and pathological findings. <i>Annals of Neurology</i> , 2003, 54, 244-247.	2.8	90
712	Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. <i>Annals of Neurology</i> , 2003, 54, 271-274.	2.8	233
713	Psychogenic Movement Disorders. <i>Canadian Journal of Neurological Sciences</i> , 2003, 30, S94-S100.	0.3	97
714	Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. <i>Neurology</i> , 2003, 60, 69-73.	1.5	771
715	Involvement of the human subthalamic nucleus in movement preparation. <i>Neurology</i> , 2003, 61, 1538-1545.	1.5	59
716	Measuring motor complications in clinical trials for early Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 143-146.	0.9	20
717	Natural History of Oppenheim's Dystonia (DYT1) in Israel. <i>Journal of Child Neurology</i> , 2003, 18, 325-330.	0.7	32
718	Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. <i>Journal of Neurosurgery</i> , 2003, 99, 489-495.	0.9	306
719	Short and long latency afferent inhibition in Parkinson's disease. <i>Brain</i> , 2003, 126, 1883-1894.	3.7	258
720	Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. <i>Neurology</i> , 2003, 60, 917-922.	1.5	113

#	ARTICLE	IF	CITATIONS
721	Subthalamic Stimulation for Parkinson's Disease â€” Living Better Electrically?. New England Journal of Medicine, 2003, 349, 1888-1891.	13.9	12
722	Stimulation of the Subthalamic Nucleus in Parkinson's Disease Does Not Produce Striatal Dopamine Release. Neurosurgery, 2003, 53, 1095-1105.	0.6	76
723	Title is missing!. Current Opinion in Neurology, 2003, 16, 523-527.	1.8	5
724	Long-term follow-up of thalamic deep brain stimulation for essential and parkinsonian tremor. Neurology, 2003, 61, 1601-1604.	1.5	204
725	The Fragile X Premutation Presenting as Essential Tremor. Archives of Neurology, 2003, 60, 117.	4.9	162
726	The cerebellothalamocortical pathway in essential tremor. Neurology, 2003, 60, 1985-1987.	1.5	97
727	Motor Cortical Stimulation for Parkinsonism in Multiple System Atrophy. Archives of Neurology, 2003, 60, 1554.	4.9	44
728	Mutations in the μ -sarcoglycan gene found to be uncommon in seven myoclonusâ€”dystonia families. Neurology, 2003, 61, 244-246.	1.5	46
729	Effects of subthalamic nucleus stimulation on motor cortex excitability in Parkinsonâ€™s disease. Neurology, 2002, 58, 1665-1672.	1.5	155
730	Practice parameter: Initiation of treatment for Parkinsonâ€™s disease: An evidence-based review. Neurology, 2002, 58, 11-17.	1.5	344
731	Predicting Motor Decline and Disability in Parkinson Disease. Archives of Neurology, 2002, 59, 1724.	4.9	179
732	Reporting clinical trials: full access to all the data. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 143-143.	0.9	0
733	Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. Journal of Neurosurgery, 2002, 97, 1152-1166.	0.9	267
734	Practice parameter: Initiation of treatment for Parkinsonâ€™s disease: An evidence-based review. Neurology, 2002, 59, 1292-1292.	1.5	11
735	A novel locus for inherited myoclonus-dystonia on 18p11. Neurology, 2002, 59, 1183-1186.	1.5	140
736	Phenocopies in a large GCH1 mutation positive family with dopa responsive dystonia: confusing the picture?. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 801-804.	0.9	31
737	Subthalamic DBS replaces levodopa in Parkinsonâ€™s disease. Neurology, 2002, 59, 1293-1294.	1.5	14
738	Reporting clinical trials. Neurology, 2002, 58, 347-348.	1.5	5

#	ARTICLE	IF	CITATIONS
739	A Controlled Trial of Rasagiline in Early Parkinson Disease. <i>Archives of Neurology</i> , 2002, 59, 1937.	4.9	559
740	Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 455.	3.8	509
741	Long-term Hardware-related Complications of Deep Brain Stimulation. <i>Neurosurgery</i> , 2002, 50, 1268-1276.	0.6	314
742	Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. <i>Brain</i> , 2002, 125, 1196-1209.	3.7	645
743	Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease With Modafinil. <i>Clinical Neuropharmacology</i> , 2002, 25, 111-114.	0.2	122
744	Long-term Hardware-related Complications of Deep Brain Stimulation. <i>Neurosurgery</i> , 2002, 50, 1268-1276.	0.6	227
745	Neonatal Ablation of the Nigrostriatal Dopamine Pathway Does Not Influence Limb Development in Rats. <i>Experimental Neurology</i> , 2002, 177, 547-556.	2.0	3
746	Effects of acute stimulation through contacts placed on the motor cortex for chronic stimulation. <i>Clinical Neurophysiology</i> , 2002, 113, 635-641.	0.7	37
747	Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. <i>Annals of Neurology</i> , 2002, 51, 604-612.	2.8	274
748	Role of SCA2 mutations in early- and late-onset dopa-responsive parkinsonism. <i>Annals of Neurology</i> , 2002, 52, 257-258.	2.8	16
749	Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. <i>Movement Disorders</i> , 2002, 17, 303-312.	2.2	183
750	Reporting clinical trials: Full access to all the data. <i>Movement Disorders</i> , 2002, 17, 3-4.	2.2	5
751	Editorial. <i>Movement Disorders</i> , 2002, 17, 1-2.	2.2	41
752	Deep brain stimulation for Parkinson's disease: Patient selection and evaluation. <i>Movement Disorders</i> , 2002, 17, S94-S101.	2.2	150
753	Management of Parkinson's disease: An evidence-based review. <i>Movement Disorders</i> , 2002, 17, i-i.	2.2	39
754	Reporting clinical trials: Full access to all the data. <i>Muscle and Nerve</i> , 2002, 25, 133-134.	1.0	0
755	Simultaneous repetitive movements following pallidotomy or subthalamic deep brain stimulation in patients with Parkinson's disease. <i>Experimental Brain Research</i> , 2002, 147, 322-331.	0.7	18
756	Reporting clinical trials: full access to all the data. <i>European Journal of Neurology</i> , 2002, 9, 123-124.	1.7	4

#	ARTICLE	IF	CITATIONS
757	Sleepiness and Sleep Attacks in Parkinson's Disease. <i>Advances in Behavioral Biology</i> , 2002, , 385-390.	0.2	0
758	Acute Effects of Levodopa and Pallidotomy on Bimanual Repetitive Arm Movements in Patients with Parkinson's Disease. <i>Advances in Behavioral Biology</i> , 2002, , 43-50.	0.2	0
759	Myoclonus in parkinsonian disorders. <i>Advances in Neurology</i> , 2002, 89, 77-83.	0.8	7
760	Potentials recorded at the scalp by stimulation near the human subthalamic nucleus. <i>Clinical Neurophysiology</i> , 2001, 112, 431-437.	0.7	127
761	Impairment of motor cortex activation and deactivation in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2001, 112, 600-607.	0.7	88
762	Effects of Apomorphine on Subthalamic Nucleus and Globus Pallidus Internus Neurons in Patients With Parkinson's Disease. <i>Journal of Neurophysiology</i> , 2001, 86, 249-260.	0.9	261
763	Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms. <i>Brain</i> , 2001, 124, 2105-2118.	3.7	168
764	Amoxapine Shows an Antipsychotic Effect but Worsens Motor Function in Patients with Parkinson's Disease and Psychosis. <i>Clinical Neuropharmacology</i> , 2001, 24, 242-244.	0.2	16
765	Deep Brain Stimulator Electrodes Used for Lesioning: Proof of Principle. <i>Neurosurgery</i> , 2001, 49, 363-369.	0.6	51
766	Essential palatal tremor. <i>Movement Disorders</i> , 2001, 16, 1202-1203.	2.2	4
767	Orthostatic tremor arises from an oscillator in the posterior fossa. <i>Movement Disorders</i> , 2001, 16, 272-279.	2.2	91
768	69-Year-old man with gait disturbance and parkinsonism. <i>Movement Disorders</i> , 2001, 16, 548-561.	2.2	1
769	Functional correlates of pallidal stimulation for Parkinson's disease. <i>Annals of Neurology</i> , 2001, 49, 155-164.	2.8	107
770	Inherited myoclonus-dystonia: Evidence supporting genetic heterogeneity. <i>Movement Disorders</i> , 2001, 16, 106-110.	2.2	40
771	Acute onset dystonic camptocormia caused by lenticular lesions. <i>Movement Disorders</i> , 2001, 16, 177-180.	2.2	64
772	Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. <i>Neurology</i> , 2001, 56, 1702-1706.	1.5	392
773	Deep-Brain Stimulation of the Subthalamic Nucleus or the Pars Interna of the Globus Pallidus in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2001, 345, 956-963.	13.9	1,538
774	Botulinum toxin for simple motor tics. <i>Neurology</i> , 2001, 56, 605-610.	1.5	208

#	ARTICLE	IF	CITATIONS
775	Effects of internal globus pallidus stimulation on motor cortex excitability. <i>Neurology</i> , 2001, 56, 716-723.	1.5	85
776	The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. <i>Human Molecular Genetics</i> , 2001, 10, 1649-1656.	1.4	133
777	Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: A PET study of resting-state glucose metabolism. <i>Brain</i> , 2001, 124, 1601-1609.	3.7	133
778	Psychiatric outcome in patients with a psychogenic movement disorder: a prospective study. <i>Neuropsychiatry, Neuropsychology and Behavioral Neurology</i> , 2001, 14, 169-76.	0.4	118
779	Update on the treatment of tics. <i>Advances in Neurology</i> , 2001, 85, 355-62.	0.8	6
780	Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. <i>Annals of Neurology</i> , 2000, 47, 369-373.	2.8	41
781	An investigation of the effects of subthalamic nucleus stimulation on acoustic measures of voice. <i>Movement Disorders</i> , 2000, 15, 1132-1138.	2.2	100
782	Botulinum Toxin for Essential Tremor of the Voice With Multiple Anatomical Sites of Tremor: A Crossover Design Study of Unilateral Versus Bilateral Injection. <i>Laryngoscope</i> , 2000, 110, 1366-1374.	1.1	120
783	Late adult onset chorea with typical pathology of Hallervorden-Spatz syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 392-395.	0.9	25
784	Relationship of lesion location to cognitive outcome following microelectrode-guided pallidotomy for Parkinson's disease: Support for the existence of cognitive circuits in the human pallidum. <i>Brain</i> , 2000, 123, 746-758.	3.7	103
785	Long-Term Follow-up of Unilateral Pallidotomy in Advanced Parkinson's Disease. <i>New England Journal of Medicine</i> , 2000, 342, 1708-1714.	13.9	263
786	Surgery for Parkinson Disease. <i>Archives of Neurology</i> , 2000, 57, 1118.	4.9	83
787	Neuropsychological Outcome of GPi Pallidotomy and GPi or STN Deep Brain Stimulation in Parkinson's Disease. <i>Brain and Cognition</i> , 2000, 42, 324-347.	0.8	255
788	A Major Locus for Myoclonus-Dystonia Maps to Chromosome 7q in Eight Families*. <i>American Journal of Human Genetics</i> , 2000, 67, 1314-1319.	2.6	15
789	Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. <i>Brain</i> , 2000, 123, 2091-2108.	3.7	488
790	A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa. <i>New England Journal of Medicine</i> , 2000, 342, 1484-1491.	13.9	1,467
791	Corticobasal ganglionic degeneration and/or frontotemporal dementia?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 705-705.	0.9	6
792	Clinical diagnostic criteria. <i>Advances in Neurology</i> , 2000, 82, 29-34.	0.8	18

#	ARTICLE	IF	CITATIONS
793	Parkinsonism in corticobasal degeneration. <i>Advances in Neurology</i> , 2000, 82, 83-9.	0.8	2
794	Surgery for levodopa-induced dyskinesias. <i>Annals of Neurology</i> , 2000, 47, S193-9; discussion S199-202.	2.8	30
795	Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease. <i>Brain</i> , 1999, 122, 405-416.	3.7	153
796	Intracranial Hypotension With Parkinsonism, Ataxia, and Bulbar Weakness. <i>Archives of Neurology</i> , 1999, 56, 869.	4.9	111
797	Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation. <i>Neurology</i> , 1999, 53, 561-561.	1.5	252
798	Dementia as the most common presentation of cortical-basal ganglionic degeneration. <i>Neurology</i> , 1999, 53, 1969-1969.	1.5	214
799	Historical and Clinical Features of Psychogenic Tremor: a Review of 70 Cases. <i>Canadian Journal of Neurological Sciences</i> , 1999, 26, 190-195.	0.3	99
800	Variability in lesion location after microelectrode-guided pallidotomy for Parkinson's disease: anatomical, physiological, and technical factors that determine lesion distribution. <i>Journal of Neurosurgery</i> , 1999, 90, 468-477.	0.9	38
801	Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. <i>Journal of Neurology</i> , 1999, 246, II1-I15.	1.8	86
802	Posteroventral medial pallidotomy in Parkinson's disease. <i>Journal of Neurology</i> , 1999, 246, II28-II41.	1.8	45
803	Essential palatal tremor: Evidence of heterogeneity based on clinical features and response to sumatriptan. <i>Movement Disorders</i> , 1999, 14, 179-180.	2.2	27
804	Factor analysis of the motor section of the unified Parkinson's disease rating scale during the off-state. <i>Movement Disorders</i> , 1999, 14, 585-589.	2.2	78
805	Motor neuron disease-inclusion dementia presenting as cortical-basal ganglionic degeneration. <i>Movement Disorders</i> , 1999, 14, 674-680.	2.2	57
806	Syringomyelic dystonia and athetosis. <i>Movement Disorders</i> , 1999, 14, 684-688.	2.2	46
807	Dose-induced penile erections in response to ropinirole therapy for Parkinson's disease. <i>Movement Disorders</i> , 1999, 14, 701-702.	2.2	40
808	Consensus statement on the diagnosis of multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 1999, 163, 94-98.	0.3	1,143
809	Cortical reflex myoclonus studied with cortical electrodes. <i>Clinical Neurophysiology</i> , 1999, 110, 1521-1530.	0.7	10
810	Neurophysiological effects of stimulation through electrodes in the human subthalamic nucleus. <i>Brain</i> , 1999, 122, 1919-1931.	3.7	152

#	ARTICLE	IF	CITATIONS
811	Globus pallidus deep brain stimulation for generalized dystonia: Clinical and PET investigation. <i>Neurology</i> , 1999, 53, 871-871.	1.5	362
812	Treatment of Early Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 1999, 26, S39-S44.	0.3	5
813	Posteroventral medial pallidotomy in advanced Parkinson's disease. <i>Advances in Neurology</i> , 1999, 80, 575-83.	0.8	7
814	Posteroventral medial pallidotomy in Parkinson's disease. <i>Journal of Neurology</i> , 1999, 246, s028-s041.	1.8	0
815	Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. <i>Annals of Neurology</i> , 1998, 44, 622-628.	2.8	653
816	Letters to the Editor. <i>Movement Disorders</i> , 1998, 13, 851-854.	2.2	53
817	Consensus statement on the diagnosis of multiple system atrophy. <i>Clinical Autonomic Research</i> , 1998, 8, 359-362.	1.4	823
818	New developments in understanding the etiology of Parkinson's disease and in its treatment. <i>Current Opinion in Neurobiology</i> , 1998, 8, 783-790.	2.0	82
819	Parkinson's Disease. <i>New England Journal of Medicine</i> , 1998, 339, 1044-1053.	13.9	1,876
820	Parkinson's Disease. <i>New England Journal of Medicine</i> , 1998, 339, 1130-1143.	13.9	1,147
821	Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. <i>Neurology</i> , 1998, 51, 850-855.	1.5	608
822	Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's disease. <i>Neurology</i> , 1998, 51, 207-215.	1.5	157
823	Immediate Motor Effects of Stimulation through Electrodes Implanted in the Human Globus Pallidus. <i>Stereotactic and Functional Neurosurgery</i> , 1998, 70, 1-18.	0.8	51
824	Pallidal Stimulation in Parkinson's Disease Patients with a Prior Unilateral Pallidotomy. <i>Canadian Journal of Neurological Sciences</i> , 1998, 25, 300-305.	0.3	74
825	Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. <i>Neurology</i> , 1998, 50, 1015-1020.	1.5	144
826	Microelectrode Recordings Define the Ventral Posteromedial Pallidotomy Target. <i>Stereotactic and Functional Neurosurgery</i> , 1998, 71, 153-163.	0.8	27
827	Pallidotomy for Parkinson's Disease. <i>Neurosurgery Clinics of North America</i> , 1998, 9, 325-336.	0.8	47
828	Corticobasal Ganglionic Degeneration and Progressive Supranuclear Palsy Presenting with Cognitive Decline. <i>Brain Pathology</i> , 1998, 8, 355-365.	2.1	89

#	ARTICLE	IF	CITATIONS
829	Pallidotomy for Tremor. <i>Movement Disorders</i> , 1998, 13, 107-110.	2.2	23
830	Surgical treatment of dystonia. <i>Advances in Neurology</i> , 1998, 78, 185-98.	0.8	14
831	Effect of GPi pallidotomy on neuropsychological function in Parkinson's Disease. <i>Archives of Clinical Neuropsychology</i> , 1997, 12, 419-419.	0.3	3
832	Olfactory dysfunction in familial parkinsonism. <i>Neurology</i> , 1997, 49, 1262-1267.	1.5	80
833	Pallidotomy Increases Cortical Inhibition in Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 1997, 24, 133-136.	0.3	17
834	Posteroventral Medial Pallidotomy in Advanced Parkinson's Disease. <i>New England Journal of Medicine</i> , 1997, 337, 1036-1043.	13.9	453
835	SECONDARY TIC DISORDERS. <i>Neurologic Clinics</i> , 1997, 15, 309-331.	0.8	67
836	Dystonia in progressive supranuclear palsy.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 62, 352-356.	0.9	113
837	Pallidal and Thalamic Surgery for Parkinson's Disease. <i>Experimental Neurology</i> , 1997, 144, 35-40.	2.0	29
838	Reversible dissociation of sensitivity to dynamic stimuli in Parkinson's disease: Is magnocellular function essential to reading motion-defined letters?. <i>Vision Research</i> , 1997, 37, 3531-3534.	0.7	16
839	Coexistence of tics and parkinsonism: Evidence for non-dopaminergic mechanisms in tic pathogenesis. <i>Neurology</i> , 1997, 49, 1699-1701.	1.5	30
840	Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. <i>Nature Medicine</i> , 1997, 3, 671-674.	15.2	216
841	Identification and characterization of neurons with tremor-frequency activity in human globus pallidus. <i>Experimental Brain Research</i> , 1997, 113, 557-563.	0.7	195
842	Neuropsychological and behavioral changes and weight gain after medial pallidotomy. <i>Annals of Neurology</i> , 1997, 41, 834-835.	2.8	53
843	High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. <i>Annals of Neurology</i> , 1997, 42, 292-299.	2.8	508
844	Effects of apomorphine on globus pallidus neurons in parkinsonian patients. <i>Annals of Neurology</i> , 1997, 42, 767-775.	2.8	189
845	Timed tests in parkinson's disease evaluation1. <i>Movement Disorders</i> , 1997, 12, 127-128.	2.2	23
846	Adult-onset subacute sclerosing panencephalitis: Case reports and review of the literature. <i>Movement Disorders</i> , 1997, 12, 342-353.	2.2	103

#	ARTICLE	IF	CITATIONS
847	Reflex myoclonus in cortical-basal ganglionic degeneration involves a transcortical pathway. <i>Movement Disorders</i> , 1997, 12, 360-369.	2.2	39
848	Teaching tape for the motor section of the toronto western spasmodic torticollis scale. <i>Movement Disorders</i> , 1997, 12, 570-575.	2.2	177
849	Inhibition of voluntary activity by thalamic stimulation in humans: Relevance for the control of tremor. <i>Movement Disorders</i> , 1997, 12, 727-737.	2.2	84
850	Globus pallidus internus pallidotomy for generalized dystonia. <i>Movement Disorders</i> , 1997, 12, 865-870.	2.2	379
851	The Effects of Pallidotomy on Parkinson's Disease: Study Design and Assessment Techniques. <i>Acta Neurochirurgica Supplementum</i> , 1997, 68, 24-28.	0.5	8
852	Cortical Degeneration in Progressive Supranuclear Palsy. A Comparison with Cortical-Basal Ganglionic Degeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 726-734.	0.9	72
853	Microelectrode recording-guided posteroventral pallidotomy in patients with Parkinson's disease. <i>Advances in Neurology</i> , 1997, 74, 167-74.	0.8	15
854	Medial pallidotomy in late-stage Parkinson's disease and striatonigral degeneration. <i>Advances in Neurology</i> , 1997, 74, 199-211.	0.8	10
855	Perioperative Problems in Parkinson's Disease and Their Management: Apomorphine with Rectal Domperidone. <i>Canadian Journal of Neurological Sciences</i> , 1996, 23, 198-203.	0.3	49
856	Normal distribution of apolipoprotein E alleles in progressive supranuclear palsy. <i>Neurology</i> , 1996, 46, 1156-1157.	1.5	27
857	Letters to the editor. <i>Movement Disorders</i> , 1996, 11, 342-345.	2.2	1
858	Idiopathic generalized myokymia (Isaacs' syndrome) with hand posturing resembling dystonia. <i>Movement Disorders</i> , 1996, 11, 448-449.	2.2	16
859	Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. <i>Annals of Neurology</i> , 1996, 39, 37-45.	2.8	329
860	Unusual clinical presentations of cortical-basal ganglionic degeneration. <i>Annals of Neurology</i> , 1996, 40, 893-900.	2.8	126
861	Atypical dopa responsive parkinsonism in a patient with megalencephaly, midbrain Lewy body disease, and some pathological features of Hallervorden-Spatz disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996, 61, 523-527.	0.9	18
862	Remoxipride in the Treatment of Levodopa-Induced Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 395-399.	0.7	12
863	Psychogenic Dystonia: a Review of 18 Cases. <i>Canadian Journal of Neurological Sciences</i> , 1995, 22, 136-143.	0.3	137
864	Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: Confirmation of 14q CAG expansion. <i>Annals of Neurology</i> , 1995, 38, 684-687.	2.8	114

#	ARTICLE	IF	CITATIONS
865	Gestes antagonistes in the suppression of tics: "Tricks for tics" Movement Disorders, 1995, 10, 226-228.	2.2	19
866	"Weight-holding tremor" An unusual task-specific form of essential tremor?. Movement Disorders, 1995, 10, 228-229.	2.2	7
867	Letters to the editor. Movement Disorders, 1995, 10, 235-237.	2.2	7
868	What is it?. Case 1, 1995: Psychosis, dementia, chorea, ataxia, and supranuclear gaze dysfunction. Movement Disorders, 1995, 10, 257-262.	2.2	23
869	Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: The spectrum of hemiparkinsonism-hemiatrophy syndrome. Movement Disorders, 1995, 10, 489-495.	2.2	30
870	Letters to the editor. Movement Disorders, 1995, 10, 527-529.	2.2	31
871	Chronic acquired hepatocerebral degeneration: Case reports and new insights. Movement Disorders, 1995, 10, 714-722.	2.2	83
872	Motor effects of stimulating the human cerebellar thalamus.. Journal of Physiology, 1995, 489, 287-298.	1.3	44
873	Factors Predictive of the Need for Levodopa Therapy in Early, Untreated Parkinson's Disease. Archives of Neurology, 1995, 52, 565-570.	4.9	53
874	Psychogenic Parkinsonism. Archives of Neurology, 1995, 52, 802-810.	4.9	125
875	Evidence for inter-generational instability in the CAG repeat in the MJD1 gene and for conserved haplotypes at flanking markers amongst Japanese and Caucasian subjects with Machado-Joseph disease. Human Molecular Genetics, 1995, 4, 1137-1146.	1.4	143
876	Effect of GPI pallidotomy on motor function in Parkinson's disease. Lancet, The, 1995, 346, 1383-1387.	6.3	620
877	Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia. The Journal of Otolaryngology, 1995, 24, 345-51.	0.6	27
878	Case 1, 1994: Rapidly progressive aphasia, apraxia, dementia, myoclonus, and parkinsonism. Movement Disorders, 1994, 9, 358-366.	2.2	18
879	Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter- and intrarater reliability assessment. Movement Disorders, 1994, 9, 390-394.	2.2	291
880	Parkinsonian syndromes associated with hydrocephalus: Case reports, a review of the literature, and pathophysiological hypotheses. Movement Disorders, 1994, 9, 508-520.	2.2	188
881	Homozygous inheritance of the Machado-Joseph disease gene. Annals of Neurology, 1994, 36, 443-447.	2.8	78
882	Striatonigral Degeneration: Iron Deposition in Putamen Correlates with the Slit-like Void Signal of Magnetic Resonance Imaging. Canadian Journal of Neurological Sciences, 1994, 21, 311-318.	0.3	61

#	ARTICLE	IF	CITATIONS
883	Differential neuronal activity in segments of globus pallidus in Parkinson's disease patients. <i>NeuroReport</i> , 1994, 5, 1533-1537.	0.6	264
884	Parietal Pick's disease mimicking cortical basal ganglionic degeneration. <i>Neurology</i> , 1994, 44, 1436-1436.	1.5	95
885	Signing tics: insights into the pathophysiology of symptoms in Tourette's syndrome. <i>Annals of Neurology</i> , 1993, 33, 212-215.	2.8	35
886	Movement sequencing disorders in parkinson's disease. <i>International Journal of Neuroscience</i> , 1993, 73, 183-194.	0.8	47
887	The spectrum of levodopa-related fluctuations in Parkinson's disease. <i>Neurology</i> , 1993, 43, 1459-1459.	1.5	152
888	Flunarizine in Essential Tremor. <i>Clinical Neuropharmacology</i> , 1993, 16, 460-463.	0.2	19
889	Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results. <i>The Journal of Otolaryngology</i> , 1993, 22, 171-5.	0.6	40
890	STIMULUS-SENSITIVE MYOCLONUS IN AKINETIC-RIGID SYNDROMES. <i>Brain</i> , 1992, 115, 1875-1888.	3.7	81
891	Cortical basal ganglionic degeneration presenting with "progressive loss of speech output and orofacial dyspraxia". <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992, 55, 1101-1101.	0.9	43
892	Can the Lombard effect be used to improve low voice intensity in Parkinson's disease?. <i>International Journal of Language and Communication Disorders</i> , 1992, 27, 121-127.	0.7	40
893	Tizanidine in Cranial Dystonia. <i>Clinical Neuropharmacology</i> , 1992, 15, 142-147.	0.2	11
894	Stiff-Person Syndrome. <i>Canadian Journal of Neurological Sciences</i> , 1992, 19, 383-388.	0.3	8
895	What is it? Case 1, 1992: Progressive gait deterioration, peripheral neuropathy, optic atrophy, bradykinesia, and dystonia in a young girl. <i>Movement Disorders</i> , 1992, 7, 373-379.	2.2	0
896	Clinical phenomenology of tic disorders selected aspects. <i>Advances in Neurology</i> , 1992, 58, 25-32.	0.8	19
897	Case 1, 1991: A severe and fatal systemic illness first presenting with a movement disorder. <i>Movement Disorders</i> , 1991, 6, 362-370.	2.2	4
898	Patient perception of tics and other movement disorders. <i>Neurology</i> , 1991, 41, 223-223.	1.5	132
899	Subcognitive Processing in the Frontocaudate "Complex Loop". <i>Alzheimer Disease and Associated Disorders</i> , 1990, 4, 150-160.	0.6	20
900	Clinical Differences Between Metoclopramide- and Antipsychotic-Induced Tardive Dyskinesias. <i>Canadian Journal of Neurological Sciences</i> , 1990, 17, 137-139.	0.3	12

#	ARTICLE	IF	CITATIONS
901	Potential benefits of dopamine striatal implant. <i>Annals of Neurology</i> , 1990, 27, 109-110.	2.8	3
902	Dopa-responsive parkinsonism with normal 6[18F]-fluorodopa positron emission tomography scans. <i>Annals of Neurology</i> , 1990, 28, 592-593.	2.8	6
903	Parkinsonism in alcohol withdrawal: A follow-up study. <i>Movement Disorders</i> , 1990, 5, 36-39.	2.2	37
904	Psychogenic dyskinesias in patients with organic movement disorders. <i>Movement Disorders</i> , 1990, 5, 127-133.	2.2	74
905	Hypoxic-ischemic damage of the basal ganglia case reports and a review of the literature. <i>Movement Disorders</i> , 1990, 5, 219-224.	2.2	139
906	Waht is it? Case 1, 1990: Progressive unilateral rigidity, bradykinesia, tremulousness, and apraxia, leading to fixed postural deformity of the involved limb. <i>Movement Disorders</i> , 1990, 5, 341-351.	2.2	24
907	Letters to the editor. <i>Movement Disorders</i> , 1990, 5, 352-355.	2.2	48
908	CQA 206-291 in Parkinson's Disease: An Acute Single Escalating Dosage Study. <i>Canadian Journal of Neurological Sciences</i> , 1990, 17, 416-419.	0.3	3
909	Corticalâ€basal ganglionic degeneration. <i>Neurology</i> , 1990, 40, 1203-1203.	1.5	508
910	Hemiballism-Hemichorea. <i>Archives of Neurology</i> , 1990, 47, 619-619.	4.9	2
911	Memory and learning in early Parkinson's disease: Evidence for a â€œfrontal lobe syndromeâ€; <i>Brain and Cognition</i> , 1990, 13, 211-232.	0.8	232
912	Frozen shoulder and other shoulder disturbances in Parkinson's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1989, 52, 63-66.	0.9	145
913	Posttraumatic movement disorders: A review. <i>Movement Disorders</i> , 1989, 4, 20-36.	2.2	119
914	Pain in Gilles de la Tourette Syndrome and Related Tic Disorders. <i>Canadian Journal of Neurological Sciences</i> , 1989, 16, 439-441.	0.3	29
915	Anticholinergic Drugs and Amantadine in the Treatment of Parkinsonâ€™s Disease. <i>Handbook of Experimental Pharmacology</i> , 1989, , 307-323.	0.9	17
916	Hemiballism in multiple sclerosis. <i>Movement Disorders</i> , 1988, 3, 88-94.	2.2	66
917	PROCEDURAL LEARNING AND NEOSTYRIAL DYSFUNCTION IN MAN. <i>Brain</i> , 1988, 111, 941-960.	3.7	546
918	Afferents contributing to the exaggerated long latency reflex response to electrical stimulation in Parkinson's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1988, 51, 1405-1410.	0.9	45

#	ARTICLE	IF	CITATIONS
919	Botulinum Toxin Injections in the Treatment of Blepharospasm, Hemifacial Spasm, and Eyelid Fasciculations. Canadian Journal of Neurological Sciences, 1988, 15, 276-280.	0.3	47
920	Idiopathic Parkinson's disease: Revised Concepts of Cognitive and Affective Status. Canadian Journal of Neurological Sciences, 1988, 15, 106-113.	0.3	21
921	Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin. Cmaj, 1988, 139, 837-44.	0.9	16
922	Dopamine agonists and antagonists in the treatment of idiopathic dystonia. Advances in Neurology, 1988, 50, 561-70.	0.8	20
923	Secondary dystonia. Advances in Neurology, 1988, 50, 9-33.	0.8	46
924	Positron tomography in dystonia. Advances in Neurology, 1988, 50, 249-53.	0.8	14
925	PARKINSON'S DISEASE. Brain, 1987, 110, 35-51.	3.7	105
926	Progressive Dystonia With Bilateral Putaminal Hypodensities. Archives of Neurology, 1987, 44, 1184-1187.	4.9	30
927	Update on Dopamine Agonists in Parkinson's Disease: "Beyond Bromocriptine" Canadian Journal of Neurological Sciences, 1987, 14, 474-482.	0.3	11
928	Manipulating the dopaminergic system in Parkinson's disease. , 1987, 32, 51-76.		7
929	A Rostrocaudal Gradient for Aromatic Acid Decarboxylase in the Human Striatum. Canadian Journal of Neurological Sciences, 1987, 14, 444-447.	0.3	32
930	Regional cerebral glucose metabolism in SLE chorea: Further evidence that striatal hypometabolism is not a correlate of chorea. Movement Disorders, 1987, 2, 201-210.	2.2	63
931	Sudden confusion with levodopa withdrawal. Movement Disorders, 1987, 2, 223-223.	2.2	4
932	What is it? Case 1, 1987: Unusual tremors, bradykinesia, and cerebral lucencies. Movement Disorders, 1987, 2, 321-338.	2.2	4
933	FRONTAL LOBE DYSFUNCTION IN PARKINSON'S DISEASE. Brain, 1986, 109, 845-883.	3.7	919
934	PAINFUL PARKINSON'S DISEASE. Lancet, The, 1986, 327, 1366-1369.	6.3	177
935	High Dose Anticholinergic Therapy in Adult Dystonia. Canadian Journal of Neurological Sciences, 1986, 13, 42-46.	0.3	35
936	Association between familial tremor and Parkinson's disease. Annals of Neurology, 1986, 19, 306-306.	2.8	17

#	ARTICLE	IF	CITATIONS
937	Levodopa dose-related fluctuations in presumed olivopontocerebellar atrophy. <i>Movement Disorders</i> , 1986, 1, 93-102.	2.2	11
938	PARKINSON'S DISEASE AND DEPRESSION. <i>Brain</i> , 1986, 109, 279-292.	3.7	161
939	Familial dystonia and visual failure with striatal CT lucencies.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1986, 49, 500-509.	0.9	44
940	Persistent Hemiballismus with Lesions Outside the Subthalamic Nucleus. <i>Canadian Journal of Neurological Sciences</i> , 1985, 12, 125-128.	0.3	49
941	Dopamine Agonists in the Treatment of Dystonia. <i>Clinical Neuropharmacology</i> , 1985, 8, 38-57.	0.2	25
942	Coexistence of Idiopathic Parkinson's Disease and Creutzfeldt-Jakob Disease. <i>Canadian Journal of Neurological Sciences</i> , 1985, 12, 272-273.	0.3	17
943	THE ANATOMICAL BASIS OF SYMPTOMATIC HEMIDYSTONIA. <i>Brain</i> , 1985, 108, 463-483.	3.7	666
944	DEMENTIA PREVALENCE IN PARKINSON'S DISEASE. <i>Lancet, The</i> , 1985, 325, 1037.	6.3	41
945	Striatal dopamine distribution in Parkinsonian patients during life. <i>Journal of the Neurological Sciences</i> , 1985, 69, 223-230.	0.3	188
946	Treatment of Parkinson's disease with agents other than Levodopa and Dopamine Agonists: controversies and new approaches. <i>Canadian Journal of Neurological Sciences</i> , 1984, 11, 210-220.	0.3	40
947	Focal paroxysmal kinesigenic choreoathetosis.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1984, 47, 1057-1058.	0.9	6
948	Lithium and parkinsonism. <i>Annals of Neurology</i> , 1984, 15, 214-214.	2.8	15
949	Diagnostic importance of immunological markers in lymphoma involving the central nervous system. <i>Annals of Neurology</i> , 1984, 16, 668-672.	2.8	24
950	A Double-Blind Trial of Clonazepam in Benign Essential Tremor. <i>Clinical Neuropharmacology</i> , 1984, 7, 83-88.	0.2	68
951	Parkinson's disease in 1984: an update. <i>Cmaj</i> , 1984, 131, 1031-7.	0.1	6
952	Long latency between the onset of motor and vocal tics in Tourette's syndrome. <i>Annals of Neurology</i> , 1983, 14, 693-694.	2.8	8
953	Spasmodic Dysphonia in Gilles de la Tourette's Disease. <i>Archives of Neurology</i> , 1983, 40, 51-52.	4.9	9
954	Dopa Dose-Dependent Sexual Deviation. <i>British Journal of Psychiatry</i> , 1983, 142, 296-298.	1.7	68

#	ARTICLE	IF	CITATIONS
955	Postanoxic symptomatic oscillatory myoclonus. <i>Neurology</i> , 1983, 33, 240-240.	1.5	47
956	Myoclonic dystonia. <i>Neurology</i> , 1983, 33, 825-825.	1.5	141
957	Pharmacology of cranial dystonia. <i>Neurology</i> , 1983, 33, 1100-1100.	1.5	16
958	Early onset of the "on-off" phenomenon in children with symptomatic Parkinsonism.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1982, 45, 823-825.	0.9	33
959	Insulin-induced hypoglycaemia does not abolish chorea.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1982, 45, 936-937.	0.9	5
960	Alphamethylparatyrosine and Tetrabenazine in Movement Disorders. <i>Clinical Neuropharmacology</i> , 1982, 5, 375-388.	0.2	30
961	Anticholinergics in Adult-Onset Focal Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 1982, 9, 313-319.	0.3	50
962	Pergolide in late-stage Parkinson disease. <i>Annals of Neurology</i> , 1982, 12, 243-247.	2.8	64
963	Alcohol and Parkinson disease. <i>Annals of Neurology</i> , 1982, 12, 254-256.	2.8	44
964	Iris pigmentation in idiopathic dystonia. <i>Annals of Neurology</i> , 1982, 12, 585-586.	2.8	2
965	Tardive dystonia. <i>Neurology</i> , 1982, 32, 1335-1335.	1.5	534
966	Movement Disorders: an Overview. , 0, , 3-19.		1
967	Acute akathisia. , 0, , 3-19.		4
968	Lessons learned: neuroprotective trials in Parkinson's disease. , 0, , 265-279.		0
969	The Clinical Spectrum of Functional/Psychogenic Dystonia. , 0, , 217-223.		0
970	Commentary: Is Tardive Dyskinesia Disappearing?. , 0, , 302-310.		1
971	Rating Scales for Movement Disorders. , 0, , 20-29.		1
972	Oculogyric Crisis Phenotype of Levodopaâ€œInduced Ocular Dyskinesia. <i>Movement Disorders Clinical Practice</i> , 0, , .	0.8	1

#	ARTICLE	IF	CITATIONS
973	Patient Selection for Movement Disorders Surgery. , 0, , 53-68.		0
974	Periodic Limb Movements While Awake (PLMA) as a manifestation of Wearingâ€™Off in Parkinson's Disease: A Case Series and Review of the Literature. Movement Disorders Clinical Practice, 0, , .	0.8	0
975	Targeted copy number variant identification across the neurodegenerative disease spectrum. Molecular Genetics & Genomic Medicine, 0, , .	0.6	3
976	Vitamins B6 and B12, levodopa, and their complex interactions in patients with Parkinsonâ€™s disease. Brain, 0, , .	3.7	2